WO1993023569A1
(en)
*
|
1992-05-11 |
1993-11-25 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for inhibiting viral replication
|
US20030206887A1
(en)
*
|
1992-05-14 |
2003-11-06 |
David Morrissey |
RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
|
US5639647A
(en)
*
|
1994-03-29 |
1997-06-17 |
Ribozyme Pharmaceuticals, Inc. |
2'-deoxy-2'alkylnucleotide containing nucleic acid
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20040219569A1
(en)
*
|
1999-07-06 |
2004-11-04 |
Fruma Yehiely |
Gene identification method
|
WO2006094406A1
(en)
*
|
2005-03-11 |
2006-09-14 |
Sarissa Inc. |
Antisense oligonucleotides targeted to the coding region of thymidylate synthase and uses thereof
|
AUPP249298A0
(en)
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
GB2353282C
(en)
|
1998-03-20 |
2013-02-27 |
State Queensland Primary Ind |
Control of gene expression
|
JP2003525017A
(ja)
*
|
1998-04-20 |
2003-08-26 |
リボザイム・ファーマシューティカルズ・インコーポレーテッド |
遺伝子発現を調節しうる新規な化学組成を有する核酸分子
|
EP2314700A1
(en)
|
1999-01-28 |
2011-04-27 |
Medical College of Georgia Research Institute, Inc |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
US7601494B2
(en)
|
1999-03-17 |
2009-10-13 |
The University Of North Carolina At Chapel Hill |
Method of screening candidate compounds for susceptibility to biliary excretion
|
EP2264166B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
US6656698B1
(en)
*
|
1999-06-30 |
2003-12-02 |
Millennium Pharmaceuticals, Inc. |
12832, a novel human kinase-like molecule and uses thereof
|
US6423885B1
(en)
|
1999-08-13 |
2002-07-23 |
Commonwealth Scientific And Industrial Research Organization (Csiro) |
Methods for obtaining modified phenotypes in plant cells
|
US8128922B2
(en)
|
1999-10-20 |
2012-03-06 |
Johns Hopkins University |
Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
|
GB9925459D0
(en)
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
DE10160151A1
(de)
*
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
US7829693B2
(en)
*
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US7179796B2
(en)
|
2000-01-18 |
2007-02-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US8273866B2
(en)
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
US20050032733A1
(en)
*
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
US8202979B2
(en)
*
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
WO2002081628A2
(en)
*
|
2001-04-05 |
2002-10-17 |
Ribozyme Pharmaceuticals, Incorporated |
Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
|
US20080039414A1
(en)
*
|
2002-02-20 |
2008-02-14 |
Sima Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
CA2403397A1
(en)
|
2000-03-16 |
2001-09-20 |
Genetica, Inc. |
Methods and compositions for rna interference
|
US8202846B2
(en)
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
US20030084471A1
(en)
*
|
2000-03-16 |
2003-05-01 |
David Beach |
Methods and compositions for RNA interference
|
EP2796553B1
(en)
*
|
2000-03-30 |
2019-06-19 |
Whitehead Institute for Biomedical Research |
RNA sequence-specific mediators of RNA interference
|
NZ553687A
(en)
*
|
2000-03-30 |
2010-03-26 |
Whitehead Biomedical Inst |
RNA sequence-specific mediators of RNA interference
|
US7662791B2
(en)
|
2000-08-02 |
2010-02-16 |
University Of Southern California |
Gene silencing using mRNA-cDNA hybrids
|
US20080242627A1
(en)
*
|
2000-08-02 |
2008-10-02 |
University Of Southern California |
Novel rna interference methods using dna-rna duplex constructs
|
US7342002B2
(en)
*
|
2000-08-03 |
2008-03-11 |
The Johns Hopkins University |
Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen
|
US20080032942A1
(en)
|
2000-08-30 |
2008-02-07 |
Mcswiggen James |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
US20030190635A1
(en)
*
|
2002-02-20 |
2003-10-09 |
Mcswiggen James A. |
RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
|
US20020165192A1
(en)
*
|
2000-09-19 |
2002-11-07 |
Kerr William G. |
Control of NK cell function and survival by modulation of ship activity
|
WO2009042910A2
(en)
*
|
2007-09-26 |
2009-04-02 |
University Of South Florida |
Ship inhibition to direct hematopoietic stem cells and induce extramedullary hematopoiesis
|
US7691821B2
(en)
*
|
2001-09-19 |
2010-04-06 |
University Of South Florida |
Inhibition of SHIP to enhance stem cell harvest and transplantation
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
SI1407044T2
(en)
*
|
2000-12-01 |
2018-03-30 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Small RNA molecules that mediate RNA interference
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
CA2369944A1
(en)
|
2001-01-31 |
2002-07-31 |
Nucleonics Inc. |
Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
|
US20050124569A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
|
US20050159378A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
WO2005014811A2
(en)
*
|
2003-08-08 |
2005-02-17 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF XIAP GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20050176025A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
|
US20050048529A1
(en)
*
|
2002-02-20 |
2005-03-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US20050159380A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050196765A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US20050124566A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
US20050287128A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
|
US20050159381A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
|
US20050054596A1
(en)
*
|
2001-11-30 |
2005-03-10 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20060142225A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
|
US20050136436A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20050191618A1
(en)
*
|
2001-05-18 |
2005-09-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
|
US20050233996A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050233997A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US20040198682A1
(en)
*
|
2001-11-30 |
2004-10-07 |
Mcswiggen James |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
|
US20050153914A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20050187174A1
(en)
*
|
2001-05-18 |
2005-08-25 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US20050256068A1
(en)
*
|
2001-05-18 |
2005-11-17 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
|
US20050196767A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
|
US7517864B2
(en)
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20070042983A1
(en)
*
|
2001-05-18 |
2007-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050159379A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
|
US20080188430A1
(en)
*
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US20050137155A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
|
US20050119212A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
|
US20050239731A1
(en)
*
|
2001-05-18 |
2005-10-27 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA)
|
US20060148743A1
(en)
*
|
2001-05-18 |
2006-07-06 |
Vasant Jadhav |
RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)
|
US20050222066A1
(en)
*
|
2001-05-18 |
2005-10-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20070093437A1
(en)
*
|
2001-05-18 |
2007-04-26 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina)
|
US20050176024A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA)
|
US20050176663A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sima Therapeutics, Inc. |
RNA interference mediated inhibition of protein tyrosine phosphatase type IVA (PRL3) gene expression using short interfering nucleic acid (siNA)
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20030175950A1
(en)
*
|
2001-05-29 |
2003-09-18 |
Mcswiggen James A. |
RNA interference mediated inhibition of HIV gene expression using short interfering RNA
|
US20050014172A1
(en)
|
2002-02-20 |
2005-01-20 |
Ivan Richards |
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
|
US20050233344A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
|
US20050158735A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
US20070270579A1
(en)
*
|
2001-05-18 |
2007-11-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20090299045A1
(en)
*
|
2001-05-18 |
2009-12-03 |
Sirna Therapeutics, Inc. |
RNA Interference Mediated Inhibition Of Interleukin and Interleukin Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20050209180A1
(en)
*
|
2001-05-18 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US20050164968A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
|
AU2004266311B2
(en)
*
|
2001-05-18 |
2009-07-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20040219671A1
(en)
*
|
2002-02-20 |
2004-11-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)
|
US20050176664A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
|
US20050282188A1
(en)
*
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050164967A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US7109165B2
(en)
*
|
2001-05-18 |
2006-09-19 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20050196781A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA)
|
US20080161256A1
(en)
*
|
2001-05-18 |
2008-07-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050079610A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US20050164224A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US20050176666A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
|
US20040019001A1
(en)
*
|
2002-02-20 |
2004-01-29 |
Mcswiggen James A. |
RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
|
US20050267058A1
(en)
*
|
2001-05-18 |
2005-12-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
|
US20060211642A1
(en)
*
|
2001-05-18 |
2006-09-21 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
US20050261219A1
(en)
*
|
2001-05-18 |
2005-11-24 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
EP1390472A4
(en)
*
|
2001-05-29 |
2004-11-17 |
Sirna Therapeutics Inc |
NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS
|
US8008472B2
(en)
|
2001-05-29 |
2011-08-30 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
|
US20050019915A1
(en)
*
|
2001-06-21 |
2005-01-27 |
Bennett C. Frank |
Antisense modulation of superoxide dismutase 1, soluble expression
|
EP2221376B1
(en)
|
2001-06-21 |
2012-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
KR101021695B1
(ko)
|
2001-07-12 |
2011-03-15 |
유니버시티 오브 매사추세츠 |
유전자 불활성화를 매개하는 소형 간섭 rna의 생체내 제조
|
DE10133858A1
(de)
*
|
2001-07-12 |
2003-02-06 |
Aventis Pharma Gmbh |
Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
|
US20030153519A1
(en)
|
2001-07-23 |
2003-08-14 |
Kay Mark A. |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
US10590418B2
(en)
*
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
US20090247606A1
(en)
*
|
2001-08-28 |
2009-10-01 |
Sirna Therapeutics, Inc. |
RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20030198627A1
(en)
*
|
2001-09-01 |
2003-10-23 |
Gert-Jan Arts |
siRNA knockout assay method and constructs
|
DE10163098B4
(de)
*
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Verfahren zur Hemmung der Replikation von Viren
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
DE10230996A1
(de)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Medikament zur Behandlung eines Pankreaskarzinoms
|
WO2003035876A1
(de)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus
|
JP2005512976A
(ja)
*
|
2001-10-26 |
2005-05-12 |
リボファーマ アーゲー |
Rna干渉により線維化疾患を処置するための医薬
|
WO2003035870A1
(de)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Medikament zur behandlung eines pankreaskarzinoms
|
US20040063654A1
(en)
*
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
AU2002348163A1
(en)
*
|
2001-11-02 |
2003-05-19 |
Intradigm Corporation |
Therapeutic methods for nucleic acid delivery vehicles
|
EP1575976A4
(en)
*
|
2001-11-02 |
2006-08-23 |
Insert Therapeutics Inc |
METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE
|
EP1445312B1
(en)
*
|
2001-11-21 |
2012-12-26 |
Astellas Pharma Inc. |
Method of inhibiting gene expression
|
US20050075304A1
(en)
*
|
2001-11-30 |
2005-04-07 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20070203333A1
(en)
*
|
2001-11-30 |
2007-08-30 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20040138163A1
(en)
*
|
2002-05-29 |
2004-07-15 |
Mcswiggen James |
RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US7294504B1
(en)
|
2001-12-27 |
2007-11-13 |
Allele Biotechnology & Pharmaceuticals, Inc. |
Methods and compositions for DNA mediated gene silencing
|
DK1465995T3
(da)
*
|
2002-01-17 |
2008-10-20 |
Univ British Columbia |
Bispespecifikke antisense-olignukleotider der inhiberer IGFBP-2 og IGFBP og fremgangsmåder til anvendelse deraf
|
DE10202419A1
(de)
*
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
GB0201477D0
(en)
*
|
2002-01-23 |
2002-03-13 |
Novartis Forschungsstiftung |
Methods of obtaining isoform specific expression in mammalian cells
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
DE60337040D1
(de)
*
|
2002-02-01 |
2011-06-16 |
Life Technologies Corp |
Oligonukleotid-Zusammensetzungen mit verbesserter Wirksamkeit
|
WO2003064621A2
(en)
*
|
2002-02-01 |
2003-08-07 |
Ambion, Inc. |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
US20050096289A1
(en)
*
|
2002-02-07 |
2005-05-05 |
Hans Prydz |
Methods and compositions for modulating tissue factor
|
CN1646695A
(zh)
*
|
2002-02-12 |
2005-07-27 |
夸克生物技术公司 |
Axl受体在诊断和治疗肾病中的应用
|
AU2003214363A1
(en)
*
|
2002-02-13 |
2003-09-04 |
Axordia Limited |
Method to modify differentiation of pluripotential stem cells
|
ES2312753T5
(es)
*
|
2002-02-14 |
2012-12-13 |
City Of Hope |
Procedimientos para producir moléculas de ARN de interferencia en células de mamífero y usos terapéuticos para tales moléculas
|
EP1501853A4
(en)
*
|
2002-02-20 |
2005-11-16 |
Sirna Therapeutics Inc |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION OF AN EPIDERMAL GROWTH FACTOR RECEPTOR USING SHORT INTERFERING NUCLEIC ACIDS
|
US7683166B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
US7700760B2
(en)
|
2002-02-20 |
2010-04-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US7662952B2
(en)
|
2002-02-20 |
2010-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
|
US7667029B2
(en)
*
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US20090137509A1
(en)
*
|
2002-02-20 |
2009-05-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATION CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
JP2005517433A
(ja)
*
|
2002-02-20 |
2005-06-16 |
サーナ・セラピューティクス・インコーポレイテッド |
短干渉核酸(siNA)を用いるTNFおよびTNFレセプタースーパーファミリー遺伝子発現のRNA干渉媒介性阻害
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
AU2003220136A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8067575B2
(en)
|
2002-02-20 |
2011-11-29 |
Merck, Sharp & Dohme Corp. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US20090093439A1
(en)
*
|
2002-02-20 |
2009-04-09 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8013143B2
(en)
|
2002-02-20 |
2011-09-06 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
|
US20100240730A1
(en)
*
|
2002-02-20 |
2010-09-23 |
Merck Sharp And Dohme Corp. |
RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA)
|
US7897753B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
|
US7897752B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
|
US7795422B2
(en)
|
2002-02-20 |
2010-09-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US7928219B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
|
US7667030B2
(en)
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US8258288B2
(en)
|
2002-02-20 |
2012-09-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
|
WO2003106476A1
(en)
*
|
2002-02-20 |
2003-12-24 |
Sirna Therapeutics, Inc |
Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
|
JP2005517450A
(ja)
*
|
2002-02-20 |
2005-06-16 |
サーナ・セラピューティクス・インコーポレイテッド |
短干渉核酸(siNA)を用いるRNA干渉媒介性標的発見および標的評価
|
US7928218B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US7928220B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
|
US20090099117A1
(en)
|
2002-02-20 |
2009-04-16 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7678897B2
(en)
|
2002-02-20 |
2010-03-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US20090192105A1
(en)
|
2002-02-20 |
2009-07-30 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
|
US20050096284A1
(en)
*
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US20090233983A1
(en)
*
|
2002-02-20 |
2009-09-17 |
Sirna Therapeutics Inc. |
RNA Interference Mediated Inhibition of Protein Tyrosine Phosphatase-1B (PTP-1B) Gene Expression Using Short Interfering RNA
|
EP1463842A4
(en)
*
|
2002-02-20 |
2006-01-25 |
Sirna Therapeutics Inc |
RNA-Interferent-mediated inhibition of protein gene expression for C-ALPHA (PKC-ALPHA) gene using SINA (Short Interfering Nucleic Acid)
|
JP2005517427A
(ja)
|
2002-02-20 |
2005-06-16 |
サーナ・セラピューティクス・インコーポレイテッド |
短干渉核酸(siNA)を用いるC型肝炎ウイルス(HCV)遺伝子発現のRNA干渉媒介性阻害
|
US7897757B2
(en)
|
2002-02-20 |
2011-03-01 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
US7935812B2
(en)
|
2002-02-20 |
2011-05-03 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US7691999B2
(en)
|
2002-02-20 |
2010-04-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
|
US7910724B2
(en)
*
|
2002-02-20 |
2011-03-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US20090253774A1
(en)
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7683165B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
EP1432724A4
(en)
*
|
2002-02-20 |
2006-02-01 |
Sirna Therapeutics Inc |
RNA inhibition mediated inhibition of MAP KINASE GENES
|
EP1495041A4
(en)
*
|
2002-02-20 |
2006-02-01 |
Sirna Therapeutics Inc |
RNA interferon-mediated inhibition of gene expression of G72 and D-amino acid oxidase (DAAO) using short-term interfering nucleic acid (siNA)
|
US20090247613A1
(en)
*
|
2002-02-20 |
2009-10-01 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20090306182A1
(en)
*
|
2002-02-20 |
2009-12-10 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MAP KINASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20090253773A1
(en)
*
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8232383B2
(en)
*
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7893248B2
(en)
|
2002-02-20 |
2011-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
WO2003072745A2
(en)
*
|
2002-02-22 |
2003-09-04 |
Eshleman James R |
Antigene locks and therapeutic uses thereof
|
WO2003073991A2
(en)
*
|
2002-03-01 |
2003-09-12 |
Celltech R & D, Inc. |
Methods to increase or decrease bone density
|
EP1572923A4
(en)
*
|
2002-03-06 |
2007-10-31 |
Rigel Pharmaceuticals Inc |
NEW METHOD FOR THE INTRODUCTION AND INTRA-CELLULAR SYNTHESIS OF SIRNA MOLECULES
|
US7274703B2
(en)
*
|
2002-03-11 |
2007-09-25 |
3Com Corporation |
Stackable network units with resiliency facility
|
JP2005521393A
(ja)
*
|
2002-03-20 |
2005-07-21 |
マサチューセッツ インスティテュート オブ テクノロジー |
Hiv治療
|
US7357928B2
(en)
|
2002-04-08 |
2008-04-15 |
University Of Louisville Research Foundation, Inc. |
Method for the diagnosis and prognosis of malignant diseases
|
CA2482904A1
(en)
|
2002-04-18 |
2003-10-23 |
Lynkeus Biotech Gmbh |
Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
|
WO2003093441A2
(en)
|
2002-05-03 |
2003-11-13 |
Duke University |
A method of regulating gene expression
|
US7199107B2
(en)
*
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
AU2003239897A1
(en)
|
2002-05-23 |
2003-12-12 |
Ceptyr, Inc. |
Modulation of ptp1b signal transduction by rna interference
|
AU2003237686A1
(en)
*
|
2002-05-24 |
2003-12-12 |
Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Rna interference mediating small rna molecules
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
US20100075423A1
(en)
*
|
2002-06-12 |
2010-03-25 |
Life Technologies Corporation |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
WO2003106630A2
(en)
*
|
2002-06-12 |
2003-12-24 |
Ambion, Inc. |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
JP2005529959A
(ja)
*
|
2002-06-14 |
2005-10-06 |
マイラス コーポレイション |
細胞へのポリヌクレオチドの伝達をするための新規な方法
|
AU2003243094B2
(en)
*
|
2002-06-21 |
2007-08-30 |
Sinogenomax Company Ltd. |
Randomised DNA libraries and double-stranded RNA libraries, use and method of production thereof
|
US7704965B2
(en)
*
|
2002-06-26 |
2010-04-27 |
The Penn State Research Foundation |
Methods and materials for treating human papillomavirus infections
|
AU2003245160B2
(en)
|
2002-06-28 |
2009-09-24 |
Arbutus Biopharma Corporation |
Method and apparatus for producing liposomes
|
ES2550609T3
(es)
|
2002-07-10 |
2015-11-11 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Interferencia de ARN mediante de moléculas de ARN de cadena sencilla
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
AU2012216354B2
(en)
*
|
2002-08-05 |
2016-01-14 |
Silence Therapeutics Gmbh |
Further novel forms of interfering RNA molecules
|
EP1389637B1
(en)
|
2002-08-05 |
2012-05-30 |
Silence Therapeutics Aktiengesellschaft |
Blunt-ended interfering RNA molecules
|
US20050042646A1
(en)
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
AU2015264957B2
(en)
*
|
2002-08-05 |
2017-10-26 |
Silence Therapeutics Gmbh |
Further novel forms of interfering rna molecules
|
HUE032289T2
(en)
*
|
2002-08-05 |
2017-09-28 |
Silence Therapeutics Gmbh |
Other new forms of interfering RNA molecules
|
US20040241854A1
(en)
|
2002-08-05 |
2004-12-02 |
Davidson Beverly L. |
siRNA-mediated gene silencing
|
SI3222724T1
(sl)
|
2002-08-05 |
2019-03-29 |
Silence Therapeutics Gmbh |
Nadaljnje nove oblike molekul interferenčne RNA
|
US20080274989A1
(en)
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
EP1550462B1
(en)
*
|
2002-08-06 |
2012-01-25 |
Toray Industries, Inc. |
Remedy or preventive for kidney disease and method of diagnosing kidney disease
|
SG166672A1
(en)
*
|
2002-08-06 |
2010-12-29 |
Intradigm Corp |
Methods of down regulating target gene expression in vivo by introduction of interfering rna
|
WO2004014933A1
(en)
|
2002-08-07 |
2004-02-19 |
University Of Massachusetts |
Compositions for rna interference and methods of use thereof
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
MXPA05001766A
(es)
*
|
2002-08-14 |
2005-08-19 |
Atugen Ag |
Uso de proteina quinasa n beta.
|
KR101212512B1
(ko)
*
|
2002-08-21 |
2012-12-26 |
더 유니버시티 오브 브리티쉬 콜롬비아 |
암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
|
US7956176B2
(en)
*
|
2002-09-05 |
2011-06-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20080260744A1
(en)
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
US20060287269A1
(en)
*
|
2002-09-09 |
2006-12-21 |
The Regents Of The University Of California |
Short interfering nucleic acid hybrids and methods thereof
|
US20040138119A1
(en)
*
|
2002-09-18 |
2004-07-15 |
Ingo Tamm |
Use of hepatitis B X-interacting protein (HBXIP) in modulation of apoptosis
|
US20060257380A1
(en)
*
|
2002-09-19 |
2006-11-16 |
Inst.Nat. De La Sante Et De La Recherche MED |
Use of sirnas for gene silencing in antigen presenting cells
|
US20050020521A1
(en)
|
2002-09-25 |
2005-01-27 |
University Of Massachusetts |
In vivo gene silencing by chemically modified and stable siRNA
|
US20060160759A1
(en)
*
|
2002-09-28 |
2006-07-20 |
Jianzhu Chen |
Influenza therapeutic
|
AU2003279004B2
(en)
*
|
2002-09-28 |
2009-10-08 |
Massachusetts Institute Of Technology |
Influenza therapeutic
|
US20040242518A1
(en)
*
|
2002-09-28 |
2004-12-02 |
Massachusetts Institute Of Technology |
Influenza therapeutic
|
US20060240425A1
(en)
*
|
2002-09-30 |
2006-10-26 |
Oncotherapy Science, Inc |
Genes and polypeptides relating to myeloid leukemia
|
US7422853B1
(en)
*
|
2002-10-04 |
2008-09-09 |
Myriad Genetics, Inc. |
RNA interference using a universal target
|
JP5449639B2
(ja)
*
|
2002-11-01 |
2014-03-19 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
HIF−1アルファのsiRNA阻害に関する組成物及び方法
|
US7892793B2
(en)
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
CA2504554A1
(en)
*
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
2'-substituted oligomeric compounds and compositions for use in gene modulations
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
EP2957568B1
(en)
|
2002-11-05 |
2016-12-21 |
Ionis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
AU2003291753B2
(en)
|
2002-11-05 |
2010-07-08 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
DE10322662A1
(de)
*
|
2002-11-06 |
2004-10-07 |
Grünenthal GmbH |
Wirksame und stabile DNA-Enzyme
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7977471B2
(en)
*
|
2002-11-14 |
2011-07-12 |
Dharmacon, Inc. |
siRNA targeting TNFα
|
US20080268457A1
(en)
*
|
2002-11-14 |
2008-10-30 |
Dharmacon, Inc. |
siRNA targeting forkhead box P3 (FOXP3)
|
US7951935B2
(en)
|
2002-11-14 |
2011-05-31 |
Dharmacon, Inc. |
siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
US7691998B2
(en)
|
2002-11-14 |
2010-04-06 |
Dharmacon, Inc. |
siRNA targeting nucleoporin 62kDa (Nup62)
|
US20090227780A1
(en)
*
|
2002-11-14 |
2009-09-10 |
Dharmacon, Inc. |
siRNA targeting connexin 43
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US8198427B1
(en)
|
2002-11-14 |
2012-06-12 |
Dharmacon, Inc. |
SiRNA targeting catenin, beta-1 (CTNNB1)
|
US7592442B2
(en)
|
2002-11-14 |
2009-09-22 |
Dharmacon, Inc. |
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
|
US7781575B2
(en)
|
2002-11-14 |
2010-08-24 |
Dharmacon, Inc. |
siRNA targeting tumor protein 53 (p53)
|
US8163896B1
(en)
|
2002-11-14 |
2012-04-24 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7619081B2
(en)
*
|
2002-11-14 |
2009-11-17 |
Dharmacon, Inc. |
siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7635770B2
(en)
|
2002-11-14 |
2009-12-22 |
Dharmacon, Inc. |
siRNA targeting protein kinase N-3 (PKN-3)
|
EP1560931B1
(en)
*
|
2002-11-14 |
2011-07-27 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
US7655785B1
(en)
|
2002-11-14 |
2010-02-02 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
US20090005548A1
(en)
*
|
2002-11-14 |
2009-01-01 |
Dharmacon, Inc. |
siRNA targeting nuclear receptor interacting protein 1 (NRIP1)
|
US7612196B2
(en)
|
2002-11-14 |
2009-11-03 |
Dharmacon, Inc. |
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
US20100113307A1
(en)
*
|
2002-11-14 |
2010-05-06 |
Dharmacon, Inc. |
siRNA targeting vascular endothelial growth factor (VEGF)
|
US10920226B2
(en)
*
|
2002-11-14 |
2021-02-16 |
Thermo Fisher Scientific Inc. |
siRNA targeting LDHA
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
US7927793B2
(en)
|
2002-11-18 |
2011-04-19 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cell lines and host nucleic acid sequences related to infectious disease
|
US7064337B2
(en)
|
2002-11-19 |
2006-06-20 |
The Regents Of The University Of California |
Radiation detection system for portable gamma-ray spectroscopy
|
DE10254214A1
(de)
*
|
2002-11-20 |
2004-06-09 |
Beiersdorf Ag |
Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz
|
EP1571209B1
(en)
*
|
2002-11-22 |
2012-06-13 |
Bio-Think Tank Co., Ltd. |
Method of detecting target base sequence of rna interference, method of designing polynucleotide base sequence causing rna interference, method of constructing double-stranded polynucleotide, method of regulating gene expression, base sequence processing apparatus, program for running base sequence
|
JP4526228B2
(ja)
*
|
2002-11-22 |
2010-08-18 |
隆 森田 |
RNAiによる新規治療法および治療剤
|
AU2003298718A1
(en)
*
|
2002-11-22 |
2004-06-18 |
University Of Massachusetts |
Modulation of hiv replication by rna interference
|
US7618948B2
(en)
*
|
2002-11-26 |
2009-11-17 |
Medtronic, Inc. |
Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
|
US7696334B1
(en)
|
2002-12-05 |
2010-04-13 |
Rosetta Genomics, Ltd. |
Bioinformatically detectable human herpesvirus 5 regulatory gene
|
CA2506714A1
(en)
*
|
2002-11-26 |
2004-06-10 |
University Of Massachusetts |
Delivery of sirnas
|
US20130130231A1
(en)
|
2002-11-26 |
2013-05-23 |
Isaac Bentwich |
Bioinformatically detectable group of novel viral regulatory genes and uses thereof
|
US7605249B2
(en)
|
2002-11-26 |
2009-10-20 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
US7829694B2
(en)
|
2002-11-26 |
2010-11-09 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
US7217807B2
(en)
|
2002-11-26 |
2007-05-15 |
Rosetta Genomics Ltd |
Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
|
CN1301263C
(zh)
|
2002-12-18 |
2007-02-21 |
北京昭衍新药研究中心 |
一组抗hiv感染及防治艾滋病的核苷酸序列及其应用
|
DK1575517T3
(da)
|
2002-12-24 |
2012-05-14 |
Rinat Neuroscience Corp |
Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
AU2004204068B8
(en)
*
|
2003-01-03 |
2010-03-25 |
Gencia Corporation |
SiRNA Mediated Post - Transcriptional Gene Silencing of Genes involved in Alopecia
|
DE602004028587D1
(de)
|
2003-01-16 |
2010-09-23 |
Univ Pennsylvania |
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON ICAM-1
|
US7629323B2
(en)
*
|
2003-01-21 |
2009-12-08 |
Northwestern University |
Manipulation of neuronal ion channels
|
US20060178297A1
(en)
*
|
2003-01-28 |
2006-08-10 |
Troy Carol M |
Systems and methods for silencing expression of a gene in a cell and uses thereof
|
US20040147027A1
(en)
*
|
2003-01-28 |
2004-07-29 |
Troy Carol M. |
Complex for facilitating delivery of dsRNA into a cell and uses thereof
|
US7732591B2
(en)
|
2003-11-25 |
2010-06-08 |
Medtronic, Inc. |
Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
|
US7994149B2
(en)
|
2003-02-03 |
2011-08-09 |
Medtronic, Inc. |
Method for treatment of Huntington's disease through intracranial delivery of sirna
|
US20040248839A1
(en)
*
|
2003-02-05 |
2004-12-09 |
University Of Massachusetts |
RNAi targeting of viruses
|
FR2850971B1
(fr)
*
|
2003-02-10 |
2006-08-11 |
Aventis Pharma Sa |
Oligonucleotide antisens inhibant l'expression de la proteine ob-rgrp et procede de detection de composes modifiant l'interaction entre la famille de la proteine ob-rgrp et le recepteur de la leptine
|
US20070104688A1
(en)
|
2003-02-13 |
2007-05-10 |
City Of Hope |
Small interfering RNA mediated transcriptional gene silencing in mammalian cells
|
US20040162235A1
(en)
*
|
2003-02-18 |
2004-08-19 |
Trubetskoy Vladimir S. |
Delivery of siRNA to cells using polyampholytes
|
EP2191846A1
(en)
|
2003-02-19 |
2010-06-02 |
Rinat Neuroscience Corp. |
Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same
|
JP2006523103A
(ja)
*
|
2003-02-21 |
2006-10-12 |
ザ ペン ステイト リサーチ ファウンデーション |
Rna干渉組成物および方法
|
US8796235B2
(en)
*
|
2003-02-21 |
2014-08-05 |
University Of South Florida |
Methods for attenuating dengue virus infection
|
ATE554185T1
(de)
|
2003-02-27 |
2012-05-15 |
Alnylam Pharmaceuticals Inc |
Verfahren und konstrukte zur bewertung von rnai- zielen und effektormolekülen
|
JPWO2004076663A1
(ja)
*
|
2003-02-27 |
2006-06-08 |
独立行政法人産業技術総合研究所 |
哺乳動物細胞におけるdsRNAによるCpG配列へのメチル化誘導
|
CA2517974A1
(en)
*
|
2003-03-05 |
2004-09-16 |
Senesco Technologies, Inc. |
Use of antisense oligonucleotides or sirna to suppress expression of eif-5a1
|
EP1604022A2
(en)
*
|
2003-03-06 |
2005-12-14 |
Oligo Engine, Inc. |
Modulation of gene expression using dna-rna hybrids
|
EP1605978B1
(en)
|
2003-03-07 |
2010-09-01 |
Alnylam Pharmaceuticals Inc. |
Therapeutic compositions
|
JP4762889B2
(ja)
*
|
2003-03-12 |
2011-08-31 |
バスジーン セラピューティクス,インコーポレイテッド |
血管形成及び腫瘍成長を阻止するための核酸化合物
|
AU2004221760B2
(en)
|
2003-03-21 |
2010-03-18 |
Roche Innovation Center Copenhagen A/S |
Short interfering RNA (siRNA) analogues
|
ATE536408T1
(de)
*
|
2003-04-02 |
2011-12-15 |
Dharmacon Inc |
Modifizierte polynukleotide zur verwendung bei rna-interferenz
|
EP1608733B1
(en)
*
|
2003-04-02 |
2011-12-07 |
Dharmacon, Inc. |
Modified polynucleotides for use in rna interference
|
US20040198640A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Dharmacon, Inc. |
Stabilized polynucleotides for use in RNA interference
|
CA2521464C
(en)
|
2003-04-09 |
2013-02-05 |
Alnylam Pharmaceuticals, Inc. |
Irna conjugates
|
EP1631669A2
(en)
|
2003-04-09 |
2006-03-08 |
Biodelivery Sciences International, Inc. |
Cochleate compositions directed against expression of proteins
|
US20070270360A1
(en)
*
|
2003-04-15 |
2007-11-22 |
Sirna Therapeutics, Inc. |
Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid
|
US8017762B2
(en)
|
2003-04-17 |
2011-09-13 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
US7723509B2
(en)
|
2003-04-17 |
2010-05-25 |
Alnylam Pharmaceuticals |
IRNA agents with biocleavable tethers
|
CA2522349A1
(en)
|
2003-04-17 |
2004-11-04 |
Alnylam Pharmaceuticals, Inc. |
Protected monomers
|
US8796436B2
(en)
|
2003-04-17 |
2014-08-05 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
EP2669377A3
(en)
|
2003-04-17 |
2015-10-14 |
Alnylam Pharmaceuticals Inc. |
Modified iRNA agents
|
US7851615B2
(en)
|
2003-04-17 |
2010-12-14 |
Alnylam Pharmaceuticals, Inc. |
Lipophilic conjugated iRNA agents
|
CA2522730A1
(en)
*
|
2003-04-18 |
2004-11-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for sirna inhibition of angiopoietin 1 and 2 and their receptor tie2
|
US20070010468A1
(en)
*
|
2003-04-23 |
2007-01-11 |
Georgetown University |
Methods and compositions for the inhibition of stat5 in prostate cancer cells
|
EP1644048B1
(en)
*
|
2003-05-05 |
2015-04-29 |
Johns Hopkins University |
Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
|
ATE516047T1
(de)
|
2003-05-09 |
2011-07-15 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und anwendungsverfahren
|
EP1623032A2
(en)
|
2003-05-09 |
2006-02-08 |
University of Pittsburgh of the Commonwealth System of Higher Education |
Small interfering rna libraries and methods of synthesis and use
|
AU2003241409A1
(en)
*
|
2003-05-12 |
2005-01-21 |
Potomac Pharmaceuticals, Inc. |
Gene expression suppression agents
|
WO2004104199A2
(en)
*
|
2003-05-15 |
2004-12-02 |
Oligo Engine, Inc. |
Modulation of gene expression using dna-dna hybrids
|
WO2005018534A2
(en)
*
|
2003-05-16 |
2005-03-03 |
Rosetta Inpharmatics, Llc |
Methods and compositions for rna interference
|
US20070243570A1
(en)
|
2003-05-19 |
2007-10-18 |
Genecare Research Institute Co., Ltd |
Apoptosis Inducer for Cancer Cell
|
AU2005212433B2
(en)
*
|
2003-05-23 |
2010-12-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sINA)
|
JP4623426B2
(ja)
*
|
2003-05-30 |
2011-02-02 |
日本新薬株式会社 |
オリゴ核酸担持複合体、当該複合体を含有する医薬組成物
|
CA2527109A1
(en)
|
2003-05-30 |
2004-12-09 |
Nippon Shinyaku Co., Ltd. |
Oligo double-stranded rna inhibiting the expression of bcl-2 and medicinal composition containing the same
|
US8309704B2
(en)
*
|
2003-06-02 |
2012-11-13 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNAi
|
DK1633767T3
(en)
|
2003-06-02 |
2019-03-25 |
Univ Massachusetts |
METHODS AND COMPOSITIONS FOR MANAGING THE EFFECT OF RNA SILENCING
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
US20050019918A1
(en)
*
|
2003-06-03 |
2005-01-27 |
Hidetoshi Sumimoto |
Treatment of cancer by inhibiting BRAF expression
|
AU2004253455B2
(en)
*
|
2003-06-03 |
2011-03-03 |
Eli Lilly And Company |
Modulation of survivin expression
|
US7595306B2
(en)
*
|
2003-06-09 |
2009-09-29 |
Alnylam Pharmaceuticals Inc |
Method of treating neurodegenerative disease
|
US8575327B2
(en)
|
2003-06-12 |
2013-11-05 |
Alnylam Pharmaceuticals, Inc. |
Conserved HBV and HCV sequences useful for gene silencing
|
DK3604537T3
(da)
|
2003-06-13 |
2022-02-28 |
Alnylam Europe Ag |
Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
|
EP1486564A1
(de)
*
|
2003-06-13 |
2004-12-15 |
Ribopharma AG |
SiRNA mit erhöhter Stabilität in Serum
|
WO2005044976A2
(en)
*
|
2003-06-20 |
2005-05-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds for use in gene modulation
|
EP1644475A4
(en)
*
|
2003-06-20 |
2009-06-03 |
Isis Pharmaceuticals Inc |
DOUBLE-STRAND COMPOSITIONS WITH A 3'-ENDO-MODIFIED STRING FOR USE IN GENE MODULATION
|
EP1692153A4
(en)
*
|
2003-07-03 |
2007-03-21 |
Univ Pennsylvania |
INHIBITION OF EXPRESSION OF SYK-KINASE
|
US20050136430A1
(en)
*
|
2003-07-15 |
2005-06-23 |
California Institute Of Technology |
Inhibitor nucleic acids
|
US20050256071A1
(en)
*
|
2003-07-15 |
2005-11-17 |
California Institute Of Technology |
Inhibitor nucleic acids
|
KR101168440B1
(ko)
*
|
2003-07-16 |
2012-07-27 |
프로티바 바이오쎄라퓨틱스, 인코포레이티드 |
지질 캡슐화된 간섭 rna
|
US20050079614A1
(en)
*
|
2003-07-21 |
2005-04-14 |
Reinhart Brenda J. |
RNAs able to modulate chromatin silencing
|
EP2530157B1
(en)
|
2003-07-31 |
2016-09-28 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of miRNAs
|
JP2007502284A
(ja)
*
|
2003-08-13 |
2007-02-08 |
ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ |
siRNAによるTGFベータII型受容体発現のサイレンシング
|
US7888497B2
(en)
|
2003-08-13 |
2011-02-15 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
US7825235B2
(en)
*
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
WO2005035759A2
(en)
*
|
2003-08-20 |
2005-04-21 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF HYPOXIA INDUCIBLE FACTOR 1 (HIF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20050136437A1
(en)
*
|
2003-08-25 |
2005-06-23 |
Nastech Pharmaceutical Company Inc. |
Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
|
SG152279A1
(en)
|
2003-08-28 |
2009-05-29 |
Novartis Ag |
Interfering rna duplex having blunt-ends and 3æ-modifications
|
US8501705B2
(en)
*
|
2003-09-11 |
2013-08-06 |
The Board Of Regents Of The University Of Texas System |
Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
|
PT2821085T
(pt)
*
|
2003-09-12 |
2020-07-28 |
Univ Massachusetts |
Interferência de arn para o tratamento de distúrbios de ganho de função
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
CN100558893C
(zh)
|
2003-09-18 |
2009-11-11 |
Isis药物公司 |
eIF4E表达的调节
|
JP2007505634A
(ja)
*
|
2003-09-22 |
2007-03-15 |
ロゼッタ インファーマティクス エルエルシー |
Rna干渉を用いる合成致死スクリーニング
|
WO2005033310A1
(de)
*
|
2003-10-01 |
2005-04-14 |
Grünenthal GmbH |
Pim-1-spezifische dsrna-verbindungen
|
US20080249038A1
(en)
*
|
2003-10-07 |
2008-10-09 |
Quark Biotech, Inc. |
Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof
|
CA2541970A1
(en)
|
2003-10-09 |
2005-06-09 |
E.I. Du Pont De Nemours And Company |
Gene silencing by using micro-rna molecules
|
WO2005045032A2
(en)
*
|
2003-10-20 |
2005-05-19 |
Sima Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP1682661A2
(en)
*
|
2003-10-23 |
2006-07-26 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
WO2005045038A2
(en)
*
|
2003-10-23 |
2005-05-19 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF GPRA AND AAA1 GENE EXPRESSION USING SHORT NUCLEIC ACID (siNA)
|
US7962316B2
(en)
|
2003-10-27 |
2011-06-14 |
Merck Sharp & Dohme Corp. |
Method of designing siRNAs for gene silencing
|
US8227434B1
(en)
|
2003-11-04 |
2012-07-24 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Materials and methods for treating oncological disorders
|
US20070275918A1
(en)
*
|
2003-11-07 |
2007-11-29 |
The Board Of Trustees Of The University Of Illinois |
Induction of Cellular Senescence by Cdk4 Disruption for Tumor Suppression and Regression
|
WO2005047507A1
(en)
*
|
2003-11-12 |
2005-05-26 |
The Austin Research Institute |
Dna-carrier conjugate
|
JP2005168485A
(ja)
*
|
2003-11-20 |
2005-06-30 |
Tsutomu Suzuki |
siRNAの設計方法
|
US7807646B1
(en)
*
|
2003-11-20 |
2010-10-05 |
University Of South Florida |
SHIP-deficiency to increase megakaryocyte progenitor production
|
US7763592B1
(en)
|
2003-11-20 |
2010-07-27 |
University Of South Florida |
SHIP-deficiency to increase megakaryocyte progenitor production
|
US20050208658A1
(en)
*
|
2003-11-21 |
2005-09-22 |
The University Of Maryland |
RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
|
US20100145038A1
(en)
*
|
2003-11-24 |
2010-06-10 |
Merck & Co., Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2005053725A2
(en)
*
|
2003-11-26 |
2005-06-16 |
The Queen's University Of Belfast |
Cancer treatment
|
JP5654722B2
(ja)
|
2003-11-26 |
2015-01-14 |
ユニバーシティ オブ マサチューセッツ |
短鎖rna機能の配列特異的阻害法
|
CA2548150A1
(en)
*
|
2003-12-04 |
2005-06-23 |
University Of South Florida |
Polynucleotides for reducing respiratory syncytial virus gene expression
|
US20050234000A1
(en)
*
|
2003-12-12 |
2005-10-20 |
Mitchell Gordon S |
SiRNA delivery into mammalian nerve cells
|
WO2005068630A1
(ja)
*
|
2003-12-16 |
2005-07-28 |
National Institute Of Advanced Industrial Science And Technology |
干渉用二重鎖rna
|
US20060134787A1
(en)
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
MXPA06007269A
(es)
*
|
2003-12-23 |
2007-07-09 |
Univ Pennsylvania |
Composiciones y metodos para terapia combinada de enfermedad.
|
JP4767019B2
(ja)
*
|
2004-01-16 |
2011-09-07 |
武田薬品工業株式会社 |
動脈硬化の予防・治療用医薬
|
EP1713912B1
(en)
*
|
2004-01-30 |
2013-09-18 |
Santaris Pharma A/S |
Modified short interfering rna (modified sirna)
|
US20050197310A1
(en)
|
2004-01-30 |
2005-09-08 |
Orna Mor |
Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
|
EP1718747B1
(en)
*
|
2004-02-06 |
2009-10-28 |
Dharmacon, Inc. |
Stabilized rnas as transfection controls and silencing reagents
|
US20060019914A1
(en)
|
2004-02-11 |
2006-01-26 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
|
US20050273868A1
(en)
*
|
2004-02-17 |
2005-12-08 |
University Of Massachusetts |
Methods and compositions for enhancing RISC activity in vitro and in vivo
|
US20060069050A1
(en)
*
|
2004-02-17 |
2006-03-30 |
University Of Massachusetts |
Methods and compositions for mediating gene silencing
|
WO2005082458A1
(en)
*
|
2004-02-23 |
2005-09-09 |
Genzyme Corporation |
Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
|
EP1566202A1
(en)
*
|
2004-02-23 |
2005-08-24 |
Sahltech I Göteborg AB |
Use of resistin antagonists in the treatment of rheumatoid arthritis
|
CA2557426A1
(en)
|
2004-02-24 |
2005-10-06 |
Thomas W. Hodge |
Rab9a, rab11a, and modulators thereof related to infectious disease
|
US7691823B2
(en)
*
|
2004-03-05 |
2010-04-06 |
University Of Massachusetts |
RIP140 regulation of glucose transport
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
US20050202075A1
(en)
*
|
2004-03-12 |
2005-09-15 |
Pardridge William M. |
Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
|
EP2899278A1
(en)
|
2004-03-12 |
2015-07-29 |
Alnylam Pharmaceuticals Inc. |
iRNA agents targeting VEGF
|
CA2559955C
(en)
*
|
2004-03-15 |
2016-02-16 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded rna
|
US20070265220A1
(en)
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
US20050208090A1
(en)
*
|
2004-03-18 |
2005-09-22 |
Medtronic, Inc. |
Methods and systems for treatment of neurological diseases of the central nervous system
|
WO2005092030A2
(en)
*
|
2004-03-22 |
2005-10-06 |
The Trustees Of The University Of Pennsylvania |
Methods of use of bcl-6-derived nucleotides to induce apoptosis
|
US20050272682A1
(en)
*
|
2004-03-22 |
2005-12-08 |
Evers Bernard M |
SiRNA targeting PI3K signal transduction pathway and siRNA-based therapy
|
WO2005097207A2
(en)
*
|
2004-03-26 |
2005-10-20 |
Curis, Inc. |
Rna interference modulators of hedgehog signaling and uses thereof
|
WO2005095622A2
(en)
*
|
2004-03-26 |
2005-10-13 |
Van Andel Research Institute |
c-met siRNA ADENOVIRUS VECTORS INHIBIT CANCER CELL GROWTH, INVASION AND TUMORIGENICITY
|
JP2005312428A
(ja)
*
|
2004-03-31 |
2005-11-10 |
Keio Gijuku |
Skp−2発現抑制を利用した癌の治療
|
JPWO2005095647A1
(ja)
*
|
2004-03-31 |
2008-02-21 |
タカラバイオ株式会社 |
siRNAのスクリーニング方法
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
EP2540734B1
(en)
*
|
2004-04-05 |
2016-03-30 |
Alnylam Pharmaceuticals, Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
EP2520652B1
(en)
|
2004-04-09 |
2015-06-10 |
Genecare Research Institute Co., Ltd |
Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
|
US20060078902A1
(en)
*
|
2004-04-15 |
2006-04-13 |
Michaeline Bunting |
Method and compositions for RNA interference
|
JP4635046B2
(ja)
*
|
2004-04-20 |
2011-02-16 |
マリナ・バイオテック・インコーポレーテッド |
哺乳類の細胞における遺伝子発現を調節するための、二本鎖rnaまたは二本鎖ハイブリッド核酸の送達を増強するための方法および組成物
|
CA2557532A1
(en)
|
2004-04-23 |
2005-11-10 |
Angela M. Christiano |
Inhibition of hairless protein mrna
|
EP1768998A2
(en)
*
|
2004-04-27 |
2007-04-04 |
Alnylam Pharmaceuticals Inc. |
Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
|
AU2005247319B2
(en)
|
2004-04-28 |
2011-12-01 |
Molecules For Health, Inc. |
Methods for treating or preventing restenosis and other vascular proliferative disorders
|
JP4584987B2
(ja)
|
2004-04-30 |
2010-11-24 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
C5修飾ピリミジンを含むオリゴヌクレオチド
|
US20060040882A1
(en)
*
|
2004-05-04 |
2006-02-23 |
Lishan Chen |
Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
|
US20110117088A1
(en)
*
|
2004-05-12 |
2011-05-19 |
Simon Michael R |
Composition and method for introduction of rna interference sequences into targeted cells and tissues
|
US20050260214A1
(en)
*
|
2004-05-12 |
2005-11-24 |
Simon Michael R |
Composition and method for introduction of RNA interference sequences into targeted cells and tissues
|
US7605250B2
(en)
*
|
2004-05-12 |
2009-10-20 |
Dharmacon, Inc. |
siRNA targeting cAMP-specific phosphodiesterase 4D
|
US20060030003A1
(en)
*
|
2004-05-12 |
2006-02-09 |
Simon Michael R |
Composition and method for introduction of RNA interference sequences into targeted cells and tissues
|
US7687616B1
(en)
|
2004-05-14 |
2010-03-30 |
Rosetta Genomics Ltd |
Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
|
WO2005111211A2
(en)
|
2004-05-14 |
2005-11-24 |
Rosetta Genomics Ltd. |
Micronas and uses thereof
|
WO2005110464A2
(en)
*
|
2004-05-14 |
2005-11-24 |
Oregon Health & Science University |
Irx5 inhibition as treatment for hyperproliferative disorders
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
EP1773303A2
(en)
*
|
2004-05-25 |
2007-04-18 |
Chimeracore, Inc. |
Self-assembling nanoparticle drug delivery system
|
US7795419B2
(en)
*
|
2004-05-26 |
2010-09-14 |
Rosetta Genomics Ltd. |
Viral and viral associated miRNAs and uses thereof
|
EP2290071B1
(en)
*
|
2004-05-28 |
2014-12-31 |
Asuragen, Inc. |
Methods and compositions involving microRNA
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
EP1602926A1
(en)
*
|
2004-06-04 |
2005-12-07 |
University of Geneva |
Novel means and methods for the treatment of hearing loss and phantom hearing
|
US7745651B2
(en)
*
|
2004-06-07 |
2010-06-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
JP4796062B2
(ja)
*
|
2004-06-07 |
2011-10-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
脂質封入干渉rna
|
US20060008907A1
(en)
*
|
2004-06-09 |
2006-01-12 |
The Curators Of The University Of Missouri |
Control of gene expression via light activated RNA interference
|
WO2006085942A2
(en)
*
|
2004-06-17 |
2006-08-17 |
The Regents Of The University Of California |
Compositions and methods for regulating gene transcription
|
US20060051815A1
(en)
*
|
2004-06-25 |
2006-03-09 |
The J. David Gladstone Institutes |
Methods of treating smooth muscle cell disorders
|
CA2572151A1
(en)
|
2004-06-30 |
2006-08-24 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a non-phosphate backbone linkage
|
EP1773857A4
(en)
*
|
2004-07-02 |
2009-05-13 |
Protiva Biotherapeutics Inc |
THE IMMUNE SYSTEM STIMULATING SIRNA MOLECULES AND APPLICATIONS THEREOF
|
WO2006038208A2
(en)
|
2004-07-12 |
2006-04-13 |
Medical Research Fund Of Tel Aviv Sourasky Medical Center |
Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment
|
CN101437834B
(zh)
*
|
2004-07-19 |
2012-06-06 |
贝勒医学院 |
细胞因子信号转导调节剂的调节和用于免疫治疗的应用
|
JP2008507341A
(ja)
*
|
2004-07-21 |
2008-03-13 |
メドトロニック,インコーポレイティド |
限局性繊維症を低減するための医療装置及び方法
|
EP1773993A2
(en)
*
|
2004-07-21 |
2007-04-18 |
Medtronic, Inc. |
METHODS FOR REDUCING OR PREVENTING LOCALIZED FIBROSIS USING SiRNA
|
EP1828215A2
(en)
|
2004-07-21 |
2007-09-05 |
Alnylam Pharmaceuticals Inc. |
Oligonucleotides comprising a modified or non-natural nucleobase
|
CA2579574A1
(en)
|
2004-07-23 |
2007-01-04 |
The University Of North Carolina At Chapel Hill |
Methods and materials for determining pain sensitivity and predicting and treating related disorders
|
US7632932B2
(en)
|
2004-08-04 |
2009-12-15 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
|
WO2006020768A2
(en)
|
2004-08-10 |
2006-02-23 |
Alnylam Pharmaceuticals, Inc. |
Chemically modified oligonucleotides
|
WO2006020557A2
(en)
*
|
2004-08-10 |
2006-02-23 |
Immusol, Inc. |
Methods of using or identifying agents that inhibit cancer growth
|
EP1789592A4
(en)
*
|
2004-08-13 |
2009-12-23 |
Univ Delaware |
METHOD FOR IDENTIFYING AND QUANTIFYING SHORT OR SMALL ARN
|
KR100939274B1
(ko)
|
2004-08-16 |
2010-01-29 |
쿠아크 파마수티칼스 인코퍼레이티드 |
알티피801 억제제의 치료적 용도
|
EP2298892A3
(en)
*
|
2004-08-23 |
2011-11-16 |
Sylentis S.A.U. |
Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs
|
US20070021366A1
(en)
*
|
2004-11-19 |
2007-01-25 |
Srivastava Satish K |
Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
|
EP1789551A2
(en)
*
|
2004-08-31 |
2007-05-30 |
Sylentis S.A.U. |
Methods and compositions to inhibit p2x7 receptor expression
|
US7323310B2
(en)
|
2004-08-31 |
2008-01-29 |
Qiagen North American Holdings, Inc. |
Methods and compositions for RNA amplification and detection using an RNA-dependent RNA-polymerase
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US20090170794A1
(en)
|
2004-09-10 |
2009-07-02 |
Somagenics Inc. |
Small interfering rnas that efficiently inhibit viral expression and methods of use thereof
|
WO2006033965A2
(en)
*
|
2004-09-16 |
2006-03-30 |
The Trustees Of The University Of Pennsylvania |
Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
|
FI20041204A0
(fi)
|
2004-09-16 |
2004-09-16 |
Riikka Lund |
Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
|
AU2005289588B2
(en)
|
2004-09-24 |
2011-12-22 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of ApoB and uses thereof
|
CA2580126C
(en)
|
2004-09-28 |
2014-08-26 |
Quark Biotech, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
|
EP1796686A4
(en)
*
|
2004-09-30 |
2008-05-14 |
Centocor Inc |
EMMPRINE ANTAGONISTS AND ITS USES
|
CN101107362A
(zh)
|
2004-10-21 |
2008-01-16 |
文甘扎公司 |
用于赋予对植物病害生物和植物病原体抗性的方法和材料
|
JP4704435B2
(ja)
*
|
2004-10-22 |
2011-06-15 |
ニューレジェニクス リミテッド |
ニューロン再生
|
US20060110440A1
(en)
*
|
2004-10-22 |
2006-05-25 |
Kiminobu Sugaya |
Method and system for biasing cellular development
|
US7790878B2
(en)
*
|
2004-10-22 |
2010-09-07 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
|
US7592322B2
(en)
*
|
2004-10-22 |
2009-09-22 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
|
JP2008517629A
(ja)
*
|
2004-10-27 |
2008-05-29 |
シェーリング コーポレイション |
Nav1.8の短い干渉核酸阻害のための組成物および方法
|
JP2008520191A
(ja)
|
2004-10-27 |
2008-06-19 |
バンダービルト・ユニバーシティ |
感染に関与する哺乳動物遺伝子
|
EP1804771A2
(en)
*
|
2004-10-28 |
2007-07-11 |
Idexx Laboratories, Inc. |
Compositions for controlled delivery of pharmaceutically active compounds
|
US20060094676A1
(en)
*
|
2004-10-29 |
2006-05-04 |
Ronit Lahav |
Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
|
WO2007001448A2
(en)
|
2004-11-04 |
2007-01-04 |
Massachusetts Institute Of Technology |
Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
|
PL2302055T3
(pl)
|
2004-11-12 |
2015-02-27 |
Asuragen Inc |
Sposoby i kompozycje z wykorzystaniem miRNA oraz cząsteczek inhibitorowych miRNA
|
US20060105052A1
(en)
*
|
2004-11-15 |
2006-05-18 |
Acar Havva Y |
Cationic nanoparticle having an inorganic core
|
US8809287B2
(en)
*
|
2004-11-15 |
2014-08-19 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for altering Wnt autocrine signaling
|
AU2005306533B2
(en)
*
|
2004-11-17 |
2012-05-31 |
Arbutus Biopharma Corporation |
siRNA silencing of apolipoprotein B
|
EP2189469B1
(en)
*
|
2004-11-18 |
2015-09-16 |
The Board Of Trustees Of The University Of Illinois |
Multicistronic siRNA constructs to inhibit tumors
|
KR101330229B1
(ko)
*
|
2004-11-19 |
2013-11-15 |
가부시키가이샤 진케어켄큐쇼 |
암세포 특이적 세포증식 억제제
|
US20060166234A1
(en)
*
|
2004-11-22 |
2006-07-27 |
Barbara Robertson |
Apparatus and system having dry control gene silencing compositions
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
US7935811B2
(en)
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
WO2006073602A2
(en)
*
|
2004-11-24 |
2006-07-13 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of the bcr-abl fusion gene and uses thereof
|
JP2008521909A
(ja)
*
|
2004-12-02 |
2008-06-26 |
ビー−ブリッジ インターナショナル,インコーポレーテッド |
短鎖干渉rna、アンチセンスポリヌクレオチド、および他のハイブリッド形成化ポリヌクレオチドの設計方法
|
US20060165667A1
(en)
*
|
2004-12-03 |
2006-07-27 |
Case Western Reserve University |
Novel methods, compositions and devices for inducing neovascularization
|
EP1824872B1
(en)
*
|
2004-12-14 |
2012-02-08 |
Alnylam Pharmaceuticals Inc. |
Rnai modulation of mll-af4 and uses thereof
|
WO2006066048A2
(en)
|
2004-12-17 |
2006-06-22 |
Beth Israel Deaconess Medical Center |
Compositions for bacterial mediated gene silencing and methods of using same
|
GB0427916D0
(en)
*
|
2004-12-21 |
2005-01-19 |
Astrazeneca Ab |
Method
|
TWI386225B
(zh)
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
用於治療眼睛病症的結締組織生長因子(CTGF)RNA干擾(RNAi)抑制技術
|
US20060142228A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
PL1830888T3
(pl)
|
2004-12-27 |
2015-12-31 |
Silence Therapeutics Gmbh |
Kompleksy lipidowe pokryte PEG i ich wykorzystanie
|
CN101124339A
(zh)
*
|
2004-12-30 |
2008-02-13 |
托德·M·豪泽 |
使用自我保护寡核苷酸调节基因表达的组合物和方法
|
AU2005322960A1
(en)
*
|
2005-01-06 |
2006-07-13 |
The Johns Hopkins University |
RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
|
DK2230304T3
(da)
*
|
2005-01-07 |
2012-07-16 |
Alnylam Pharmaceuticals Inc |
IRNA-modulering af RSV og terapeutiske anvendelser deraf
|
DE602006013275D1
(de)
|
2005-01-07 |
2010-05-12 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
WO2006081192A2
(en)
*
|
2005-01-24 |
2006-08-03 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of the nogo-l or nogo-r gene and uses thereof
|
EP1846026A4
(en)
*
|
2005-01-26 |
2008-07-02 |
Univ Johns Hopkins |
ANTICANCER DNA VACCINE USING PLASMID CODING ANTIGEN AND CALRETICULIN SUCH AS MUTANT ONCOPROTEINS
|
TW200639253A
(en)
*
|
2005-02-01 |
2006-11-16 |
Alcon Inc |
RNAi-mediated inhibition of ocular targets
|
US8088579B2
(en)
|
2005-02-14 |
2012-01-03 |
University Of Iowa Research Foundation |
Complement factor H for diagnosis of age-related macular degeneration
|
EP1848805A2
(en)
*
|
2005-02-14 |
2007-10-31 |
HVC Strategic Research Institute, Inc |
Pharmaceutical agents for preventing metastasis of cancer
|
WO2006102970A2
(en)
*
|
2005-03-08 |
2006-10-05 |
Qiagen Gmbh |
Modified short interfering rna
|
MX2007010608A
(es)
|
2005-03-11 |
2007-10-19 |
Alcon Inc |
Inhibicion mediada por i-arn de proteina i relacionada con frizzled para tratamiento de glaucoma.
|
GB0505081D0
(en)
*
|
2005-03-14 |
2005-04-20 |
Genomica Sau |
Downregulation of interleukin-12 expression by means of rnai technology
|
WO2006130201A1
(en)
*
|
2005-03-14 |
2006-12-07 |
Board Of Regents, The University Of Texas System |
Antigene oligomers inhibit transcription
|
JP4585342B2
(ja)
*
|
2005-03-18 |
2010-11-24 |
株式会社資生堂 |
不全角化を抑制する物質のスクリーニング方法、同方法によりスクリーニングされた物質及び不全角化を抑制する方法
|
EP1877556B1
(en)
*
|
2005-03-25 |
2011-09-14 |
Medtronic, Inc. |
Use of anti-tnf or anti-il1 rnai to suppress pro- inflammatory cytokine actions locally to treat pain
|
WO2006105361A2
(en)
*
|
2005-03-31 |
2006-10-05 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
WO2006113743A2
(en)
*
|
2005-04-18 |
2006-10-26 |
Massachusetts Institute Of Technology |
Compositions and methods for rna interference with sialidase expression and uses thereof
|
US7902352B2
(en)
|
2005-05-06 |
2011-03-08 |
Medtronic, Inc. |
Isolated nucleic acid duplex for reducing huntington gene expression
|
EP1885854B1
(en)
|
2005-05-06 |
2012-10-17 |
Medtronic, Inc. |
Methods and sequences to suppress primate huntington gene expression
|
JP5329949B2
(ja)
*
|
2005-05-31 |
2013-10-30 |
エコーレ ポリテクニーク フェデラーレ デ ローザンヌ |
遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
|
US20070048293A1
(en)
*
|
2005-05-31 |
2007-03-01 |
The Trustees Of The University Of Pennsylvania |
Manipulation of PTEN in T cells as a strategy to modulate immune responses
|
EP1888749B1
(en)
|
2005-06-01 |
2014-10-15 |
Polyplus Transfection |
Oligonucleotides for rna interference and biological applications thereof
|
AU2006252456A1
(en)
*
|
2005-06-01 |
2006-12-07 |
Duke University |
Method of inhibiting intimal hyperplasia
|
CN100445381C
(zh)
*
|
2005-06-10 |
2008-12-24 |
中国人民解放军军事医学科学院基础医学研究所 |
带有单链polyA尾巴的siRNA分子制备方法和应用
|
US20100266574A1
(en)
*
|
2005-06-10 |
2010-10-21 |
Orna Mor |
Oligoribonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases
|
WO2006138145A1
(en)
|
2005-06-14 |
2006-12-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
US7838503B2
(en)
*
|
2005-06-15 |
2010-11-23 |
Children's Medical Center Corporation |
Methods for extending the replicative lifespan of cells
|
FI20050640A0
(fi)
*
|
2005-06-16 |
2005-06-16 |
Faron Pharmaceuticals Oy |
Yhdisteitä amiinioksidaasista riippuvien sairauksien tai häiriöiden hoitoon tai estoon
|
CN101501055B
(zh)
*
|
2005-06-23 |
2016-05-11 |
贝勒医学院 |
负性免疫调节因子的调节和免疫疗法应用
|
CA2608964A1
(en)
*
|
2005-06-27 |
2007-01-04 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of hif-1 and therapeutic uses thereof
|
US9133517B2
(en)
|
2005-06-28 |
2015-09-15 |
Medtronics, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin
|
CA2614531C
(en)
*
|
2005-07-07 |
2015-06-16 |
Avraham Hochberg |
Nucleic acid agents for downregulating h19, and methods of using same
|
US8703769B2
(en)
|
2005-07-15 |
2014-04-22 |
The University Of North Carolina At Chapel Hill |
Use of EGFR inhibitors to prevent or treat obesity
|
WO2007012329A2
(de)
*
|
2005-07-25 |
2007-02-01 |
Technische Universität Dresden |
Rna-abhängige rna-polymerase, verfahren und kits zur amplifikation und / oder markierung von rna
|
US20070111227A1
(en)
*
|
2005-07-28 |
2007-05-17 |
Green Pamela J |
Small regulatory RNAs and methods of use
|
US7919583B2
(en)
|
2005-08-08 |
2011-04-05 |
Discovery Genomics, Inc. |
Integration-site directed vector systems
|
US20070213257A1
(en)
*
|
2005-08-12 |
2007-09-13 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for complexes of nucleic acids and peptides
|
WO2007022506A2
(en)
|
2005-08-18 |
2007-02-22 |
University Of Massachusetts |
Methods and compositions for treating neurological disease
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
US8501703B2
(en)
|
2005-08-30 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
WO2007030167A1
(en)
*
|
2005-09-02 |
2007-03-15 |
Nastech Pharmaceutical Company Inc. |
Modification of double-stranded ribonucleic acid molecules
|
US20090221673A1
(en)
*
|
2005-09-13 |
2009-09-03 |
Rigby William F C |
Compositions and Methods for Regulating RNA Translation via CD154 CA-Dinucleotide Repeat
|
AU2006298844B2
(en)
|
2005-09-20 |
2012-01-12 |
Basf Plant Science Gmbh |
Methods for controlling gene expression using ta-siRAN
|
FR2890859B1
(fr)
*
|
2005-09-21 |
2012-12-21 |
Oreal |
Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
|
WO2007041213A2
(en)
*
|
2005-09-30 |
2007-04-12 |
St. Jude Children's Research Hospital |
Methods for regulation of p53 translation and function
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
WO2007048046A2
(en)
*
|
2005-10-20 |
2007-04-26 |
Protiva Biotherapeutics, Inc. |
Sirna silencing of filovirus gene expression
|
GB0521351D0
(en)
*
|
2005-10-20 |
2005-11-30 |
Genomica Sau |
Modulation of TRPV expression levels
|
GB0521716D0
(en)
*
|
2005-10-25 |
2005-11-30 |
Genomica Sau |
Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
|
US8076307B2
(en)
*
|
2005-10-27 |
2011-12-13 |
National University Corporation NARA Institute of Science and Technology |
Formation/elongation of axon by inhibiting the expression or function of Singar and application to nerve regeneration
|
US7320965B2
(en)
|
2005-10-28 |
2008-01-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Huntingtin gene
|
AU2006308765B2
(en)
|
2005-11-02 |
2013-09-05 |
Arbutus Biopharma Corporation |
Modified siRNA molecules and uses thereof
|
AU2006311725B2
(en)
*
|
2005-11-04 |
2011-11-24 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of NAV1.8 gene
|
US8076308B2
(en)
*
|
2005-11-07 |
2011-12-13 |
British Columbia Cancer Agency |
Inhibition of autophagy genes in cancer chemotherapy
|
AU2006311730B2
(en)
|
2005-11-09 |
2010-12-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Factor V Leiden mutant gene
|
CA2629664A1
(en)
|
2005-11-17 |
2007-08-02 |
Board Of Regents, The University Of Texas System |
Modulation of gene expression by oligomers targeted to chromosomal dna
|
US8916530B2
(en)
*
|
2005-11-18 |
2014-12-23 |
Gradalis, Inc. |
Individualized cancer therapy
|
US8603991B2
(en)
|
2005-11-18 |
2013-12-10 |
Gradalis, Inc. |
Individualized cancer therapy
|
US20080125384A1
(en)
*
|
2005-11-21 |
2008-05-29 |
Shuewi Yang |
Simultaneous silencing and restoration of gene function
|
WO2007061022A1
(ja)
*
|
2005-11-24 |
2007-05-31 |
Jichi Medical University |
プロヒビチン2(phb2)のミトコンドリア機能
|
WO2007070682A2
(en)
|
2005-12-15 |
2007-06-21 |
Massachusetts Institute Of Technology |
System for screening particles
|
ATE466081T1
(de)
*
|
2005-12-22 |
2010-05-15 |
Opko Ophthalmics Llc |
Zusammensetzungen und verfahren zur regulierung eines komplementsystems
|
AR057252A1
(es)
*
|
2005-12-27 |
2007-11-21 |
Alcon Mfg Ltd |
Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
|
JP5713377B2
(ja)
*
|
2005-12-28 |
2015-05-07 |
ザ スクリプス リサーチ インスティテュート |
薬物標的としての天然アンチセンスおよび非コードrna転写物
|
US8673873B1
(en)
*
|
2005-12-28 |
2014-03-18 |
Alcon Research, Ltd. |
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
|
EP1973574B1
(en)
*
|
2005-12-30 |
2014-04-02 |
Institut Gustave Roussy |
Use of inhibitors of scinderin and/or of ephrin-a1 for treating tumors
|
EP1974040B1
(en)
|
2006-01-17 |
2012-10-03 |
Biolex Therapeutics, Inc. |
Compositions and methods for humanization and optimization of N-glycans in plants
|
US20090060921A1
(en)
*
|
2006-01-17 |
2009-03-05 |
Biolex Therapeutics, Inc. |
Glycan-optimized anti-cd20 antibodies
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
DK2671954T3
(en)
|
2006-01-20 |
2018-08-13 |
Cell Signaling Technology Inc |
Translocation and mutant ROS kinase in human non-small cell lung carcinoma
|
DOP2007000015A
(es)
|
2006-01-20 |
2007-08-31 |
Quark Biotech Inc |
Usos terapéuticos de inhibidores de rtp801
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
US20070259827A1
(en)
*
|
2006-01-25 |
2007-11-08 |
University Of Massachusetts |
Compositions and methods for enhancing discriminatory RNA interference
|
EP1984382B1
(en)
*
|
2006-01-27 |
2012-08-15 |
Santaris Pharma A/S |
Lna modified phosphorothiolated oligonucleotides
|
US8229398B2
(en)
*
|
2006-01-30 |
2012-07-24 |
Qualcomm Incorporated |
GSM authentication in a CDMA network
|
US8362229B2
(en)
*
|
2006-02-08 |
2013-01-29 |
Quark Pharmaceuticals, Inc. |
Tandem siRNAS
|
US7910566B2
(en)
|
2006-03-09 |
2011-03-22 |
Quark Pharmaceuticals Inc. |
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
|
FI20060246A0
(fi)
*
|
2006-03-16 |
2006-03-16 |
Jukka Westermarck |
Uusi kasvua stimuloiva proteiini ja sen käyttö
|
WO2007109609A2
(en)
*
|
2006-03-17 |
2007-09-27 |
The Board Of Trustees Of The University Of Illinois |
Method for inhibiting angiogenesis
|
WO2007107162A2
(en)
|
2006-03-23 |
2007-09-27 |
Santaris Pharma A/S |
Small internally segmented interfering rna
|
US7956177B2
(en)
*
|
2006-03-24 |
2011-06-07 |
Alnylam Pharmaceuticals, Inc. |
dsRNA compositions and methods for treating HPV infection
|
FR2898908A1
(fr)
|
2006-03-24 |
2007-09-28 |
Agronomique Inst Nat Rech |
Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
|
US20070238691A1
(en)
*
|
2006-03-29 |
2007-10-11 |
Senesco Technologies, Inc. |
Inhibition of HIV replication and expression of p24 with eIF-5A
|
JP2009534309A
(ja)
|
2006-03-31 |
2009-09-24 |
マサチューセッツ インスティテュート オブ テクノロジー |
治療剤の標的化送達のためのシステム
|
NZ571568A
(en)
|
2006-03-31 |
2010-11-26 |
Alnylam Pharmaceuticals Inc |
Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene
|
WO2007113331A2
(en)
*
|
2006-04-06 |
2007-10-11 |
Dkfz Deutsches Krebsforschungszentrum |
Method to inhibit the propagation of an undesired cell population
|
CA2648581A1
(en)
*
|
2006-04-07 |
2008-09-12 |
Chimeros, Inc. |
Compositions and methods for treating b- cell malignancies
|
JP5524610B2
(ja)
|
2006-04-07 |
2014-06-18 |
ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク |
トランスコバラミン受容体ポリペプチド、核酸およびその調節因子、ならびに細胞の増殖の調節ならびにガンおよびコバラミン欠損症の処置に使用する関連方法
|
US9044461B2
(en)
|
2006-04-07 |
2015-06-02 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
EP2016177A2
(en)
*
|
2006-04-12 |
2009-01-21 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hepcidin
|
US20100055116A1
(en)
*
|
2006-04-13 |
2010-03-04 |
Liou Hsiou-Chi |
Methods and Compositions for Targeting c-Rel
|
AU2007238608A1
(en)
|
2006-04-14 |
2007-10-25 |
Massachusetts Institute Of Technology |
Identifying and modulating molecular pathways that mediate nervous system plasticity
|
DK2447359T3
(en)
|
2006-04-14 |
2016-02-08 |
Cell Signaling Technology Inc |
Genetic defects and mutated ALK kinase in human solid tumors
|
JP4812874B2
(ja)
*
|
2006-04-28 |
2011-11-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Jcウイルス遺伝子の発現を抑制するための組成物および方法
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
US7605251B2
(en)
*
|
2006-05-11 |
2009-10-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the PCSK9 gene
|
WO2007133758A1
(en)
*
|
2006-05-15 |
2007-11-22 |
Physical Pharmaceutica, Llc |
Composition and improved method for preparation of small particles
|
EP2019691B1
(en)
|
2006-05-15 |
2020-08-12 |
Massachusetts Institute of Technology |
Polymers for functional particles
|
US20070269892A1
(en)
*
|
2006-05-18 |
2007-11-22 |
Nastech Pharmaceutical Company Inc. |
FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
|
ATE528008T1
(de)
*
|
2006-05-19 |
2011-10-15 |
Alnylam Pharmaceuticals Inc |
Rnai-modulation von aha und ihre therapeutische verwendung
|
JP2009537179A
(ja)
*
|
2006-05-19 |
2009-10-29 |
ザ スクリップス リサーチ インスティテュート |
蛋白質ミスフォールディングの処置
|
EP2018443A4
(en)
*
|
2006-05-22 |
2009-11-11 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS INHIBITING EXPRESSION OF IKK-B GENE
|
US9273356B2
(en)
|
2006-05-24 |
2016-03-01 |
Medtronic, Inc. |
Methods and kits for linking polymorphic sequences to expanded repeat mutations
|
US20070275923A1
(en)
*
|
2006-05-25 |
2007-11-29 |
Nastech Pharmaceutical Company Inc. |
CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
|
GB0610542D0
(en)
*
|
2006-05-26 |
2006-07-05 |
Medical Res Council |
Screening method
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
WO2007141796A2
(en)
|
2006-06-09 |
2007-12-13 |
Quark Pharmaceuticals, Inc. |
Therapeutic uses of inhibitors of rtp801l
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
US20080152654A1
(en)
*
|
2006-06-12 |
2008-06-26 |
Exegenics, Inc., D/B/A Opko Health, Inc. |
COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
|
US9200275B2
(en)
*
|
2006-06-14 |
2015-12-01 |
Merck Sharp & Dohme Corp. |
Methods and compositions for regulating cell cycle progression
|
US9381477B2
(en)
|
2006-06-23 |
2016-07-05 |
Massachusetts Institute Of Technology |
Microfluidic synthesis of organic nanoparticles
|
US8124752B2
(en)
*
|
2006-07-10 |
2012-02-28 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the MYC gene
|
GB0613753D0
(en)
*
|
2006-07-11 |
2006-08-23 |
Norwegian Radium Hospital Res |
Method
|
EP2046807B1
(en)
|
2006-07-13 |
2012-03-28 |
University of Iowa Research Foundation |
Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
|
JP4756271B2
(ja)
*
|
2006-07-18 |
2011-08-24 |
独立行政法人産業技術総合研究所 |
ガン細胞の老化、アポトーシス誘導剤
|
EP2049658A2
(en)
*
|
2006-07-21 |
2009-04-22 |
Silence Therapeutics AG |
Means for inhibiting the expression of protein kinase 3
|
US20080039415A1
(en)
*
|
2006-08-11 |
2008-02-14 |
Gregory Robert Stewart |
Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
|
US20100330105A1
(en)
*
|
2006-08-22 |
2010-12-30 |
John Hopkins University |
Anticancer Combination Therapies
|
DE102006039479A1
(de)
|
2006-08-23 |
2008-03-06 |
Febit Biotech Gmbh |
Programmierbare Oligonukleotidsynthese
|
US7872118B2
(en)
*
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
AU2007299748A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
miR-15, miR-26, miR -31,miR -145, miR-147, miR-188, miR-215, miR-216 miR-331, mmu-miR-292-3p regulated genes and pathways as targets for therapeutic intervention
|
EP2076599A2
(en)
*
|
2006-09-19 |
2009-07-08 |
Asuragen, Inc. |
Mir-200 regulated genes and pathways as targets for therapeutic intervention
|
EP2066687A4
(en)
|
2006-09-21 |
2010-12-08 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HAMP GENE
|
AU2007299705B2
(en)
|
2006-09-22 |
2012-09-06 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
|
SG166778A1
(en)
*
|
2006-10-11 |
2010-12-29 |
Max Planck Gesellschaft |
Influenza targets
|
WO2008063760A2
(en)
*
|
2006-10-18 |
2008-05-29 |
The University Of Texas M.D. Anderson Cancer Center |
Methods for treating cancer targeting transglutaminase
|
JP2010507387A
(ja)
*
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のsiRNAおよびその使用方法
|
US20100062436A1
(en)
|
2006-10-31 |
2010-03-11 |
Noxxon Pharma Ag |
Methods for Detection of a Single- or Double-Stranded Nucleic Acid Molecule
|
US9279127B2
(en)
|
2006-11-01 |
2016-03-08 |
The Medical Research Fund At The Tel-Aviv Sourasky Medical Center |
Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
|
US8324367B2
(en)
|
2006-11-03 |
2012-12-04 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
US9375440B2
(en)
|
2006-11-03 |
2016-06-28 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
US8252526B2
(en)
*
|
2006-11-09 |
2012-08-28 |
Gradalis, Inc. |
ShRNA molecules and methods of use thereof
|
US8906874B2
(en)
|
2006-11-09 |
2014-12-09 |
Gradalis, Inc. |
Bi-functional shRNA targeting Stathmin 1 and uses thereof
|
US8758998B2
(en)
|
2006-11-09 |
2014-06-24 |
Gradalis, Inc. |
Construction of bifunctional short hairpin RNA
|
US8034921B2
(en)
*
|
2006-11-21 |
2011-10-11 |
Alnylam Pharmaceuticals, Inc. |
IRNA agents targeting CCR5 expressing cells and uses thereof
|
US7819842B2
(en)
|
2006-11-21 |
2010-10-26 |
Medtronic, Inc. |
Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites
|
US7988668B2
(en)
|
2006-11-21 |
2011-08-02 |
Medtronic, Inc. |
Microsyringe for pre-packaged delivery of pharmaceuticals
|
EP2087912B1
(en)
*
|
2006-11-22 |
2017-05-10 |
The University of Tokyo |
Sirna carrier using disulfide-bridged polymeric micelle
|
CA2670696A1
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
WO2008152446A2
(en)
|
2006-11-27 |
2008-12-18 |
Patrys Limited |
Novel glycosylated peptide target in neoplastic cells
|
WO2008067373A2
(en)
*
|
2006-11-28 |
2008-06-05 |
Alcon Research, Ltd. |
RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS
|
US20080261907A1
(en)
*
|
2006-11-30 |
2008-10-23 |
University Of Southern California |
Compositions and methods of sphingosine kinase inhibitors in radiation therapy of various cancers
|
WO2008073920A2
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
Mir-21 regulated genes and pathways as targets for therapeutic intervention
|
AU2007333109A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
Functions and targets of let-7 micro RNAs
|
KR20090098818A
(ko)
*
|
2006-12-14 |
2009-09-17 |
노파르티스 아게 |
근육병 및 심혈관병 치료를 위한 조성물 및 방법
|
CA2671270A1
(en)
*
|
2006-12-29 |
2008-07-17 |
Asuragen, Inc. |
Mir-16 regulated genes and pathways as targets for therapeutic intervention
|
US7754698B2
(en)
*
|
2007-01-09 |
2010-07-13 |
Isis Pharmaceuticals, Inc. |
Modulation of FR-alpha expression
|
US9896511B2
(en)
|
2007-01-10 |
2018-02-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
|
EP3042959A1
(en)
|
2007-01-16 |
2016-07-13 |
The University of Queensland |
Method of inducing an immune response
|
US20080171906A1
(en)
*
|
2007-01-16 |
2008-07-17 |
Everaerts Frank J L |
Tissue performance via hydrolysis and cross-linking
|
CA2674683A1
(en)
*
|
2007-01-16 |
2008-07-24 |
The Burnham Institute For Medical Research |
Compositions and methods for treatment of colorectal cancer
|
CA2675964C
(en)
*
|
2007-01-16 |
2015-12-22 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
H19 silencing nucleic acid agents for treating rheumatoid arthritis
|
US8361988B2
(en)
*
|
2007-01-17 |
2013-01-29 |
Institut De Recherches Cliniques De Montreal |
Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use
|
EP2117305A4
(en)
|
2007-01-26 |
2011-03-30 |
Univ Louisville Res Found |
MODIFICATION OF EXOXIC COMPONENTS USED AS VACCINE
|
WO2008093331A1
(en)
*
|
2007-01-29 |
2008-08-07 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Antibody conjugates for circumventing multi-drug resistance
|
US20100183696A1
(en)
*
|
2007-01-30 |
2010-07-22 |
Allergan, Inc |
Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists
|
EP2134830A2
(en)
|
2007-02-09 |
2009-12-23 |
Massachusetts Institute of Technology |
Oscillating cell culture bioreactor
|
CA2691066C
(en)
|
2007-02-09 |
2018-07-31 |
Northwestern University |
Particles for detecting intracellular targets
|
DE102007008596B4
(de)
|
2007-02-15 |
2010-09-02 |
Friedrich-Schiller-Universität Jena |
Biologisch wirksame Moleküle auf Grundlage von PNA und siRNA, Verfahren zu deren zellspezifischen Aktivierung sowie Applikationskit zur Verabreichung
|
WO2008103643A1
(en)
*
|
2007-02-20 |
2008-08-28 |
Monsanto Technology, Llc |
Invertebrate micrornas
|
WO2008106102A2
(en)
|
2007-02-26 |
2008-09-04 |
Quark Pharmaceuticals, Inc. |
Inhibitors of rtp801 and their use in disease treatment
|
US20100292301A1
(en)
*
|
2007-02-28 |
2010-11-18 |
Elena Feinstein |
Novel sirna structures
|
WO2008109034A2
(en)
*
|
2007-03-02 |
2008-09-12 |
The Trustees Of The University Of Pennsylvania |
Modulating pdx-1 with pcif1, methods and uses thereof
|
WO2008109518A1
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
|
US20080299659A1
(en)
*
|
2007-03-02 |
2008-12-04 |
Nastech Pharmaceutical Company Inc. |
Nucleic acid compounds for inhibiting apob gene expression and uses thereof
|
US9085638B2
(en)
|
2007-03-07 |
2015-07-21 |
The Johns Hopkins University |
DNA vaccine enhancement with MHC class II activators
|
US20080260765A1
(en)
*
|
2007-03-15 |
2008-10-23 |
Johns Hopkins University |
HPV DNA Vaccines and Methods of Use Thereof
|
US7812002B2
(en)
|
2007-03-21 |
2010-10-12 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
|
WO2008116094A2
(en)
|
2007-03-21 |
2008-09-25 |
Brookhaven Science Associates, Llc |
Combined hairpin-antisense compositions and methods for modulating expression
|
PE20090064A1
(es)
*
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
US7759320B2
(en)
|
2007-03-29 |
2010-07-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the Ebola
|
WO2008124634A1
(en)
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Polymer-encapsulated reverse micelles
|
EP2144600A4
(en)
|
2007-04-04 |
2011-03-16 |
Massachusetts Inst Technology |
POLY (AMINIC ACID) TARGET MOLECULES
|
CA2683063A1
(en)
*
|
2007-04-09 |
2008-10-16 |
Chimeros, Inc. |
Self-assembling nanoparticle drug delivery system
|
JP5258874B2
(ja)
|
2007-04-10 |
2013-08-07 |
キアゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Rna干渉タグ
|
WO2008131129A2
(en)
*
|
2007-04-17 |
2008-10-30 |
Baxter International Inc. |
Nucleic acid microparticles for pulmonary delivery
|
AU2008242583B2
(en)
*
|
2007-04-23 |
2013-10-10 |
Alnylam Pharmaceuticals, Inc. |
Glycoconjugates of RNA interference agents
|
WO2008143774A2
(en)
*
|
2007-05-01 |
2008-11-27 |
University Of Massachusetts |
Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
|
EP2607477B1
(en)
|
2007-05-03 |
2020-09-23 |
The Brigham and Women's Hospital, Inc. |
Multipotent stem cells and uses thereof
|
JP5296328B2
(ja)
*
|
2007-05-09 |
2013-09-25 |
独立行政法人理化学研究所 |
1本鎖環状rnaおよびその製造方法
|
AU2008254907A1
(en)
*
|
2007-05-15 |
2008-11-27 |
Helicon Therapeutics, Inc. |
Methods of identifying genes involved in memory formation using small interfering RNA(siRNA)
|
AU2008254905A1
(en)
*
|
2007-05-15 |
2008-11-27 |
Helicon Therapeutics, Inc. |
Methods of treating cognitive disorders by inhibition of Gpr12
|
US20090131354A1
(en)
*
|
2007-05-22 |
2009-05-21 |
Bader Andreas G |
miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
|
EP2162538B1
(en)
|
2007-05-22 |
2016-04-20 |
Arcturus Therapeutics, Inc. |
Oligomers for therapeutics
|
DK2160464T3
(da)
|
2007-05-30 |
2014-08-04 |
Univ Northwestern |
Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser
|
EP2166843A4
(en)
|
2007-06-01 |
2010-08-11 |
Univ Princeton |
TREATMENT OF VIRUS INFECTIONS BY MODULATION OF HOST CELL METABOLISMS
|
WO2008153029A1
(ja)
*
|
2007-06-11 |
2008-12-18 |
Takara Bio Inc. |
特異的遺伝子発現方法
|
US20100273854A1
(en)
*
|
2007-06-15 |
2010-10-28 |
Hagar Kalinski |
Compositions and methods for inhibiting nadph oxidase expression
|
AR066984A1
(es)
*
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
|
SI2170403T1
(sl)
|
2007-06-27 |
2014-07-31 |
Quark Pharmaceuticals, Inc. |
Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov
|
WO2009004995A1
(ja)
*
|
2007-06-29 |
2009-01-08 |
Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. |
生理活性物質を定着および発現させる方法
|
WO2009004085A2
(en)
*
|
2007-07-05 |
2009-01-08 |
Novartis Ag |
Dsrna for treating viral infection
|
ES2423182T3
(es)
|
2007-07-10 |
2013-09-18 |
Neurim Pharmaceuticals (1991) Ltd. |
Variantes de unión CD44 en las enfermedades neurodegenerativas
|
US8828960B2
(en)
*
|
2007-07-17 |
2014-09-09 |
Idexx Laboratories, Inc. |
Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
|
JP2009033986A
(ja)
*
|
2007-07-31 |
2009-02-19 |
Sumitomo Chemical Co Ltd |
RNA干渉による遺伝子発現抑制のためのターゲット遺伝子としてのcar遺伝子の使用
|
EP2030615A3
(en)
|
2007-08-13 |
2009-12-02 |
ELFORD, Howard L. |
Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
|
US8501929B2
(en)
*
|
2007-08-17 |
2013-08-06 |
Biochrom Pharma Inc. |
PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease
|
JP2010537640A
(ja)
*
|
2007-08-27 |
2010-12-09 |
ボストン バイオメディカル, インコーポレイテッド |
マイクロrna模倣剤または阻害剤としての非対称性rna二重鎖の組成物
|
US8637477B2
(en)
*
|
2007-08-30 |
2014-01-28 |
Akshaya Bio Inc. |
Antigenic compositions and use of same in the targeted delivery of nucleic acids
|
US20090081789A1
(en)
*
|
2007-08-31 |
2009-03-26 |
Greenville Hospital System |
Activation of nuclear factor kappa B
|
WO2009033027A2
(en)
|
2007-09-05 |
2009-03-12 |
Medtronic, Inc. |
Suppression of scn9a gene expression and/or function for the treatment of pain
|
US8361714B2
(en)
|
2007-09-14 |
2013-01-29 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
EP2207570A2
(en)
*
|
2007-09-14 |
2010-07-21 |
Nitto Denko Corporation |
Drug carriers
|
JP5049713B2
(ja)
*
|
2007-09-14 |
2012-10-17 |
株式会社コナミデジタルエンタテインメント |
ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置
|
JP5723154B2
(ja)
|
2007-09-19 |
2015-05-27 |
アプライド バイオシステムズ リミテッド ライアビリティー カンパニー |
RNAiにおけるオフターゲット表現型の影響を減少させるためのSiRNA配列非依存性修飾フォーマットおよびその安定化型
|
EP2197454A4
(en)
*
|
2007-09-25 |
2012-07-04 |
Idexx Lab Inc |
PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
|
PL2644192T3
(pl)
|
2007-09-28 |
2017-09-29 |
Pfizer Inc. |
Ukierunkowanie na komórki nowotworowe z zastosowaniem nanocząstek
|
US20120082659A1
(en)
*
|
2007-10-02 |
2012-04-05 |
Hartmut Land |
Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
|
EP2231168A4
(en)
*
|
2007-10-03 |
2012-01-04 |
Quark Pharmaceuticals Inc |
NEW STRUCTURES OF ARNSI
|
WO2009046397A2
(en)
*
|
2007-10-04 |
2009-04-09 |
Board Of Regents, The University Of Texas System |
Modulating gene expression with agrna and gapmers targeting antisense transcripts
|
CN101861165A
(zh)
|
2007-10-12 |
2010-10-13 |
麻省理工学院 |
疫苗纳米技术
|
EP3741851A1
(en)
|
2007-10-18 |
2020-11-25 |
Cell Signaling Technology, Inc. |
Translocation and mutant ros kinase in human non-small cell lung carcinoma
|
US8097712B2
(en)
|
2007-11-07 |
2012-01-17 |
Beelogics Inc. |
Compositions for conferring tolerance to viral disease in social insects, and the use thereof
|
US20100098664A1
(en)
*
|
2007-11-28 |
2010-04-22 |
Mathieu Jean-Francois Desclaux |
Lentiviral vectors allowing RNAi mediated inhibition of GFAP and vimentin expression
|
JP2011505144A
(ja)
*
|
2007-11-30 |
2011-02-24 |
ベイラー カレッジ オブ メディシン |
樹状細胞ワクチン組成物およびその使用
|
US8071562B2
(en)
*
|
2007-12-01 |
2011-12-06 |
Mirna Therapeutics, Inc. |
MiR-124 regulated genes and pathways as targets for therapeutic intervention
|
EP2268664B1
(en)
|
2007-12-03 |
2017-05-24 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Doc1 compositions and methods for treating cancer
|
US8507455B2
(en)
*
|
2007-12-04 |
2013-08-13 |
Alnylam Pharmaceuticals, Inc. |
Folate conjugates
|
US20090247608A1
(en)
|
2007-12-04 |
2009-10-01 |
Alnylam Pharmaceuticals, Inc. |
Targeting Lipids
|
CA2707042A1
(en)
|
2007-12-10 |
2009-06-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor vii gene
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
US20110105584A1
(en)
*
|
2007-12-12 |
2011-05-05 |
Elena Feinstein |
Rtp80il sirna compounds and methods of use thereof
|
WO2009076679A2
(en)
|
2007-12-13 |
2009-06-18 |
Alnylam Pharmaceuticals Inc. |
Methods and compositions for prevention or treatment of rsv infection
|
US20090176729A1
(en)
*
|
2007-12-14 |
2009-07-09 |
Alnylam Pharmaceuticals, Inc. |
Method of treating neurodegenerative disease
|
US7845686B2
(en)
*
|
2007-12-17 |
2010-12-07 |
S & B Technical Products, Inc. |
Restrained pipe joining system for plastic pipe
|
KR100949791B1
(ko)
*
|
2007-12-18 |
2010-03-30 |
이동기 |
오프-타겟 효과를 최소화하고 RNAi 기구를 포화시키지않는 신규한 siRNA 구조 및 그 용도
|
US20090192114A1
(en)
*
|
2007-12-21 |
2009-07-30 |
Dmitriy Ovcharenko |
miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
|
WO2009090639A2
(en)
*
|
2008-01-15 |
2009-07-23 |
Quark Pharmaceuticals, Inc. |
Sirna compounds and methods of use thereof
|
AU2009241591A1
(en)
*
|
2008-01-31 |
2009-11-05 |
Alnylam Pharmaceuticals, Inc. |
Optimized methods for delivery of DSRNA targeting the PCSK9 gene
|
US20090263803A1
(en)
*
|
2008-02-08 |
2009-10-22 |
Sylvie Beaudenon |
Mirnas differentially expressed in lymph nodes from cancer patients
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
WO2009102427A2
(en)
|
2008-02-11 |
2009-08-20 |
Rxi Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
US7977321B2
(en)
*
|
2008-02-12 |
2011-07-12 |
University Of Tennessee Research Foundation |
Small interfering RNAs targeting feline herpes virus
|
EP2250266A2
(en)
|
2008-02-12 |
2010-11-17 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of cd45 gene
|
DE102009043743B4
(de)
|
2009-03-13 |
2016-10-13 |
Friedrich-Schiller-Universität Jena |
Zellspezifisch wirksame Moleküle auf Grundlage von siRNA sowie Applikationskits zu deren Herstellung und Verwendung
|
JP2011515072A
(ja)
*
|
2008-02-13 |
2011-05-19 |
エラン ファーマ インターナショナル リミテッド |
α−シヌクレインキナーゼ
|
WO2009103067A2
(en)
*
|
2008-02-14 |
2009-08-20 |
The Children's Hospital Of Philadelphia |
Compositions and methods to treat asthma
|
EP2265276A2
(en)
*
|
2008-03-05 |
2010-12-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 and vegf genes
|
US20090233297A1
(en)
*
|
2008-03-06 |
2009-09-17 |
Elizabeth Mambo |
Microrna markers for recurrence of colorectal cancer
|
JP5653899B2
(ja)
*
|
2008-03-17 |
2015-01-14 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
神経筋シナプスの維持および再生に関与するマイクロrnaの同定
|
MX2010010303A
(es)
*
|
2008-03-20 |
2010-10-20 |
Quark Pharmaceuticals Inc |
Nuevos compuestos de acido ribonucleico de pequeña interferencia para inhibir rtp801.
|
WO2009154835A2
(en)
*
|
2008-03-26 |
2009-12-23 |
Asuragen, Inc. |
Compositions and methods related to mir-16 and therapy of prostate cancer
|
EP2105145A1
(en)
*
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Method for muscle-specific delivery lipid-conjugated oligonucleotides
|
EP2264167B1
(en)
*
|
2008-03-31 |
2016-10-12 |
National Institute of Advanced Industrial Science and Technology |
Double-stranded lipid-modified rna having high rna interference effect
|
TWI348916B
(en)
*
|
2008-04-03 |
2011-09-21 |
Univ Nat Taiwan |
A novel treatment tool for cancer: rna interference of bcas2
|
WO2009126726A1
(en)
*
|
2008-04-08 |
2009-10-15 |
Asuragen, Inc |
Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
|
CA2721183C
(en)
|
2008-04-11 |
2019-07-16 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
EP2271368B1
(en)
|
2008-04-11 |
2018-12-05 |
Cedars-Sinai Medical Center |
Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery
|
PL2279254T3
(pl)
|
2008-04-15 |
2017-11-30 |
Protiva Biotherapeutics Inc. |
Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
|
EP2285385A4
(en)
*
|
2008-04-15 |
2013-01-16 |
Quark Pharmaceuticals Inc |
COMPOUNDS BASED ON RNSI TO INHIBIT NRF2
|
US20090285861A1
(en)
*
|
2008-04-17 |
2009-11-19 |
Tzyy-Choou Wu |
Tumor cell-based cancer immunotherapeutic compositions and methods
|
WO2009129465A2
(en)
*
|
2008-04-17 |
2009-10-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of xbp-1 gene
|
USRE48948E1
(en)
|
2008-04-18 |
2022-03-01 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable polymer
|
JP5773366B2
(ja)
|
2008-04-21 |
2015-09-02 |
ティシュー リジェネレイション セラピューティックス、インコーポレイテッド |
生物学的又は化学的作用物質に対する予防又はそれらの治療のために遺伝子改変されたヒト臍帯血管周囲細胞
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
US8173616B2
(en)
*
|
2008-05-02 |
2012-05-08 |
The Brigham And Women's Hospital, Inc. |
RNA-induced translational silencing and cellular apoptosis
|
WO2009137807A2
(en)
|
2008-05-08 |
2009-11-12 |
Asuragen, Inc. |
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
US20090291073A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Ward Keith W |
Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
|
WO2009146417A1
(en)
*
|
2008-05-30 |
2009-12-03 |
Sigma-Aldrich Co. |
Compositions and methods for specifically silencing a target nucleic acid
|
WO2009149182A1
(en)
|
2008-06-04 |
2009-12-10 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small rna targeting of gene promoters
|
US20090305611A1
(en)
*
|
2008-06-06 |
2009-12-10 |
Flow International Corporation |
Device and method for improving accuracy of a high-pressure fluid jet apparatus
|
EP2293800B1
(en)
|
2008-06-06 |
2016-10-05 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treatment of ear disorders
|
US20110053226A1
(en)
*
|
2008-06-13 |
2011-03-03 |
Riboxx Gmbh |
Method for enzymatic synthesis of chemically modified rna
|
WO2010005741A1
(en)
*
|
2008-06-16 |
2010-01-14 |
Georgia Tech Research Corporation |
Nanogels for cellular delivery of therapeutics
|
TWI455944B
(zh)
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
US20110184046A1
(en)
*
|
2008-07-11 |
2011-07-28 |
Dinah Wen-Yee Sah |
Compositions And Methods For Inhibiting Expression Of GSK-3 Genes
|
WO2010008562A2
(en)
|
2008-07-16 |
2010-01-21 |
Recombinetics |
Methods and materials for producing transgenic animals
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
US8039658B2
(en)
*
|
2008-07-25 |
2011-10-18 |
Air Products And Chemicals, Inc. |
Removal of trace arsenic impurities from triethylphosphate (TEPO)
|
WO2010014857A2
(en)
*
|
2008-07-30 |
2010-02-04 |
University Of Massachusetts |
Chromosome therapy
|
WO2010021720A1
(en)
|
2008-08-19 |
2010-02-25 |
Nektar Therapeutics |
Conjugates of small-interfering nucleic acids
|
CN107083386A
(zh)
*
|
2008-08-25 |
2017-08-22 |
埃克斯雷德制药有限公司 |
阻止***生长因子的反义核苷酸及其用途
|
WO2011028218A1
(en)
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Process for triphosphate oligonucleotide synthesis
|
MX345116B
(es)
*
|
2008-09-15 |
2017-01-17 |
Children's Medical Center Corp |
Modulacion de bcl11a para tratamiento de hemoglobinopatias.
|
EP3336188B1
(en)
|
2008-09-22 |
2020-05-06 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering rnai compounds
|
CA2737661C
(en)
|
2008-09-23 |
2019-08-20 |
Alnylam Pharmaceuticals, Inc. |
Chemical modifications of monomers and oligonucleotides with cycloaddition
|
EP3584320A1
(en)
|
2008-09-25 |
2019-12-25 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
EP2344638A1
(en)
*
|
2008-10-06 |
2011-07-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of an rna from west nile virus
|
WO2010042292A1
(en)
*
|
2008-10-08 |
2010-04-15 |
Trustees Of Dartmouth College |
Method for selectively inhibiting the activity of acat1 in the treatment of alzheimer's disease
|
US9149492B2
(en)
|
2008-10-08 |
2015-10-06 |
Trustees Of Dartmouth College |
Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease
|
US8802646B2
(en)
*
|
2008-10-08 |
2014-08-12 |
Trustees Of Dartmouth College |
Method for selectively inhibiting the activity of ACAT1 in the treatment of alzheimer's disease
|
US9388413B2
(en)
|
2008-10-08 |
2016-07-12 |
Trustees Of Dartmouth College |
Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
|
US9388414B2
(en)
|
2008-10-08 |
2016-07-12 |
Trustees Of Dartmouth College |
Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
|
EP3225621A1
(en)
|
2008-10-09 |
2017-10-04 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
US8343498B2
(en)
|
2008-10-12 |
2013-01-01 |
Massachusetts Institute Of Technology |
Adjuvant incorporation in immunonanotherapeutics
|
US8591905B2
(en)
|
2008-10-12 |
2013-11-26 |
The Brigham And Women's Hospital, Inc. |
Nicotine immunonanotherapeutics
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
US8277812B2
(en)
|
2008-10-12 |
2012-10-02 |
Massachusetts Institute Of Technology |
Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
|
US9458472B2
(en)
*
|
2008-10-15 |
2016-10-04 |
Massachusetts Institute Of Technology |
Detection and destruction of cancer cells using programmed genetic vectors
|
JP2012505657A
(ja)
|
2008-10-15 |
2012-03-08 |
ソマジェニックス インク. |
遺伝子発現の阻害のためのショートヘアピンrna
|
EA020312B1
(ru)
*
|
2008-10-20 |
2014-10-30 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы для ингибирования экспрессии транстиретина
|
EP2350277A1
(en)
*
|
2008-10-23 |
2011-08-03 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
|
US20110190380A1
(en)
*
|
2008-10-23 |
2011-08-04 |
Elena Feinstein |
Methods for delivery of sirna to bone marrow cells and uses thereof
|
EP4241767A3
(en)
|
2008-11-10 |
2023-11-01 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
US20100179213A1
(en)
*
|
2008-11-11 |
2010-07-15 |
Mirna Therapeutics, Inc. |
Methods and Compositions Involving miRNAs In Cancer Stem Cells
|
PL2365804T3
(pl)
*
|
2008-11-13 |
2015-10-30 |
Modgene Llc |
Zmniejszanie obciążenia amyloidem-beta w tkance niemózgowej
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
US8268797B2
(en)
|
2008-11-21 |
2012-09-18 |
Isis Pharmaceuticals, Inc. |
Combination therapy for the treatment of cancer
|
JP5749172B2
(ja)
|
2008-11-24 |
2015-07-15 |
ノースウェスタン ユニバーシティ |
多価rna−ナノ粒子組成物
|
EP2191834A1
(en)
*
|
2008-11-26 |
2010-06-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Compositions and methods for treating retrovirus infections
|
JP5816556B2
(ja)
|
2008-12-03 |
2015-11-18 |
アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. |
治療剤のためのunaオリゴマー構造
|
CA2745832A1
(en)
|
2008-12-04 |
2010-06-10 |
Opko Ophthalmics, Llc |
Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
|
US20100291188A1
(en)
*
|
2008-12-04 |
2010-11-18 |
Musc Foundation For Research Development |
Periostin Inhibitory Compositions for Myocardial Regeneration, Methods of Delivery, and Methods of Using Same
|
HRP20240240T1
(hr)
|
2008-12-09 |
2024-04-26 |
F. Hoffmann - La Roche Ag |
Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
|
NZ593618A
(en)
*
|
2008-12-10 |
2013-02-22 |
Alnylam Pharmaceuticals Inc |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
EP2356236B1
(en)
*
|
2008-12-11 |
2015-07-29 |
Xiangxue Group (Hong Kong) Company Limited |
siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION
|
JPWO2010067882A1
(ja)
*
|
2008-12-12 |
2012-05-24 |
株式会社クレハ |
癌及び喘息治療のための医薬組成物
|
EP2370175A2
(en)
|
2008-12-16 |
2011-10-05 |
Bristol-Myers Squibb Company |
Methods of inhibiting quiescent tumor proliferation
|
US20110288155A1
(en)
|
2008-12-18 |
2011-11-24 |
Elena Feinstein |
Sirna compounds and methods of use thereof
|
KR101209265B1
(ko)
|
2008-12-26 |
2012-12-06 |
주식회사 삼양바이오팜 |
음이온성 약물 함유 약제학적 조성물 및 그 제조방법
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
US8980820B2
(en)
*
|
2009-01-19 |
2015-03-17 |
The Research Foundation For The State University Of New York |
Fatty acid binding proteins as drug targets for endocannabinoids
|
US8741862B2
(en)
*
|
2009-01-20 |
2014-06-03 |
Vib Vzw |
PHD2 inhibition for blood vessel normalization, and uses thereof
|
US9023820B2
(en)
|
2009-01-26 |
2015-05-05 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein C-III expression
|
WO2010089221A1
(en)
*
|
2009-02-03 |
2010-08-12 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of ptp1b genes
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
CA2744236C
(en)
|
2009-02-12 |
2021-03-16 |
Cell Signaling Technology, Inc. |
Mutant ros expression in human cancer
|
JP2012518401A
(ja)
|
2009-02-24 |
2012-08-16 |
リボックス・ゲーエムベーハー |
低分子干渉rnaの改善された設計
|
WO2010101951A1
(en)
|
2009-03-02 |
2010-09-10 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
EP2408917A2
(en)
*
|
2009-03-19 |
2012-01-25 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
|
CN104861066B
(zh)
|
2009-03-23 |
2018-05-08 |
夸克制药公司 |
治疗癌症和纤维化疾病的化合物组合物和方法
|
US20100239632A1
(en)
|
2009-03-23 |
2010-09-23 |
Warsaw Orthopedic, Inc. |
Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
|
WO2010120874A2
(en)
|
2009-04-14 |
2010-10-21 |
Chimeros, Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
WO2010124231A2
(en)
*
|
2009-04-24 |
2010-10-28 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
|
US8367350B2
(en)
|
2009-04-29 |
2013-02-05 |
Morehouse School Of Medicine |
Compositions and methods for diagnosis, prognosis and management of malaria
|
MX352992B
(es)
|
2009-05-05 |
2017-12-15 |
Beeologics Inc |
Prevencion y tratamiento de la enfermedad de nosema en abejas.
|
US8933049B2
(en)
*
|
2009-05-05 |
2015-01-13 |
Medical Diagnostic Laboratories, Llc |
Repressor on IFN-λ promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-λ gene activity
|
US9255266B2
(en)
*
|
2009-05-06 |
2016-02-09 |
Rutgers, The State University Of New Jersey |
RNA targeting in alpha-synucleinopathies
|
CN102427852A
(zh)
*
|
2009-05-15 |
2012-04-25 |
霍夫曼-拉罗奇有限公司 |
用于抑制糖皮质素受体(gcr)基因表达的组合物和方法
|
CA2762524A1
(en)
*
|
2009-05-18 |
2011-01-13 |
Ensysce Biosciences, Inc. |
Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
|
WO2011019423A2
(en)
|
2009-05-20 |
2011-02-17 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
WO2010135669A1
(en)
*
|
2009-05-22 |
2010-11-25 |
Sabiosciences Corporation |
Arrays and methods for reverse genetic functional analysis
|
CN102575252B
(zh)
|
2009-06-01 |
2016-04-20 |
光环生物干扰疗法公司 |
用于多价rna干扰的多核苷酸、组合物及其使用方法
|
US20120083519A1
(en)
*
|
2009-06-03 |
2012-04-05 |
Djillali Sahali |
Methods For Diagnosing And Treating A Renal Disease In An Individual
|
AU2010256356B2
(en)
|
2009-06-05 |
2015-07-16 |
University Of Florida Research Foundation, Inc. |
Isolation and targeted suppression of lignin biosynthetic genes from sugarcane
|
WO2010144336A2
(en)
|
2009-06-08 |
2010-12-16 |
Quark Pharmaceuticals, Inc. |
Methods for treating chronic kidney disease
|
CA2764609C
(en)
|
2009-06-10 |
2018-10-02 |
Alnylam Pharmaceuticals, Inc. |
Improved cationic lipid of formula i
|
EP2440666B1
(en)
|
2009-06-10 |
2017-03-01 |
Temasek Life Sciences Laboratory Limited |
Virus induced gene silencing (vigs) for functional analysis of genes in cotton
|
KR20120050429A
(ko)
*
|
2009-06-15 |
2012-05-18 |
알닐람 파마슈티칼스 인코포레이티드 |
Pcsk9 유전자를 표적으로 하는 지질 제형된 dsrna
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
US20100324124A1
(en)
*
|
2009-06-17 |
2010-12-23 |
Massachusetts Institute Of Technology |
Compositions and methods relating to DNA-based particles
|
US20100323018A1
(en)
*
|
2009-06-17 |
2010-12-23 |
Massachusetts Institute Of Technology |
Branched DNA/RNA monomers and uses thereof
|
GB0910723D0
(en)
*
|
2009-06-22 |
2009-08-05 |
Sylentis Sau |
Novel drugs for inhibition of gene expression
|
EP2449114B9
(en)
|
2009-07-01 |
2017-04-19 |
Protiva Biotherapeutics Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
US8871730B2
(en)
|
2009-07-13 |
2014-10-28 |
Somagenics Inc. |
Chemical modification of short small hairpin RNAs for inhibition of gene expression
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
JP5589077B2
(ja)
|
2009-07-20 |
2014-09-10 |
ブリストル−マイヤーズ スクイブ カンパニー |
増殖性疾患の相乗的処置のための抗ctla4抗体と多様な治療レジメンとの組み合わせ
|
WO2011020024A2
(en)
|
2009-08-13 |
2011-02-17 |
The Johns Hopkins University |
Methods of modulating immune function
|
WO2011020023A2
(en)
|
2009-08-14 |
2011-02-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
AP3412A
(en)
|
2009-08-24 |
2015-09-30 |
Phigenix Inc |
Targeting pax2 for the treatment of breast cancer
|
EP2475388B1
(en)
|
2009-09-10 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Use of il-33 antagonists to treat fibrotic disease
|
WO2011032100A1
(en)
|
2009-09-11 |
2011-03-17 |
Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Inhibitors of kshv vil6 and human il6
|
EP2295543A1
(en)
|
2009-09-11 |
2011-03-16 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Method for the preparation of an influenza virus
|
CN107519133A
(zh)
|
2009-09-15 |
2017-12-29 |
阿尔尼拉姆医药品有限公司 |
脂质配制的组合物及抑制Eg5和VEGF基因的表达的方法
|
WO2011035065A1
(en)
|
2009-09-17 |
2011-03-24 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
US9187746B2
(en)
|
2009-09-22 |
2015-11-17 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting siRNA agents
|
WO2011038160A2
(en)
*
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
US20150025122A1
(en)
|
2009-10-12 |
2015-01-22 |
Larry J. Smith |
Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
|
US8962584B2
(en)
|
2009-10-14 |
2015-02-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Compositions for controlling Varroa mites in bees
|
AU2010313154B2
(en)
|
2009-10-30 |
2016-05-12 |
Northwestern University |
Templated nanoconjugates
|
US9101643B2
(en)
|
2009-11-03 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
|
US9799416B2
(en)
*
|
2009-11-06 |
2017-10-24 |
Terrapower, Llc |
Methods and systems for migrating fuel assemblies in a nuclear fission reactor
|
WO2011057171A1
(en)
|
2009-11-08 |
2011-05-12 |
Quark Pharmaceuticals, Inc. |
METHODS FOR DELIVERY OF siRNA TO THE SPINAL CORD AND THERAPIES ARISING THEREFROM
|
CN102770529B
(zh)
|
2009-11-17 |
2018-06-05 |
Musc研究发展基金会 |
针对人核仁素的人单克隆抗体
|
WO2011066475A1
(en)
|
2009-11-26 |
2011-06-03 |
Quark Pharmaceuticals, Inc. |
Sirna compounds comprising terminal substitutions
|
US9687550B2
(en)
|
2009-12-07 |
2017-06-27 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
EP2862929B1
(en)
|
2009-12-09 |
2017-09-06 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating diseases, disorders or injury of the CNS
|
KR101692063B1
(ko)
*
|
2009-12-09 |
2017-01-03 |
닛토덴코 가부시키가이샤 |
hsp47 발현의 조절
|
EP2509421B1
(en)
|
2009-12-10 |
2020-02-05 |
Cedars-Sinai Medical Center |
Drug delivery of temozolomide for systemic based treatment of cancer
|
EP2336171A1
(en)
|
2009-12-11 |
2011-06-22 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel targets for the treatment of proliferative diseases
|
EP2513308B1
(en)
|
2009-12-17 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Modulation of pilr to treat immune disorders
|
NZ600725A
(en)
|
2009-12-18 |
2015-08-28 |
Univ British Colombia |
Methods and compositions for delivery of nucleic acids
|
US8293718B2
(en)
|
2009-12-18 |
2012-10-23 |
Novartis Ag |
Organic compositions to treat HSF1-related diseases
|
US8933046B2
(en)
|
2009-12-23 |
2015-01-13 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. |
Influenza targets
|
WO2011079077A1
(en)
|
2009-12-23 |
2011-06-30 |
Gradalis, Inc. |
Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
|
US20130023578A1
(en)
|
2009-12-31 |
2013-01-24 |
Samyang Biopharmaceuticals Corporation |
siRNA for inhibition of c-Met expression and anticancer composition containing the same
|
TW201124159A
(en)
*
|
2010-01-07 |
2011-07-16 |
Univ Nat Cheng Kung |
Small interference RNA molecule and applications thereof
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
US9200277B2
(en)
*
|
2010-01-11 |
2015-12-01 |
Curna, Inc. |
Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
|
WO2011088058A1
(en)
*
|
2010-01-12 |
2011-07-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expressions of factor vii and pten genes
|
DE102010004957A1
(de)
|
2010-01-14 |
2011-07-21 |
Universitätsklinikum Jena, 07743 |
Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
WO2011100131A2
(en)
|
2010-01-28 |
2011-08-18 |
Alnylam Pharmacuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
US8722641B2
(en)
|
2010-01-29 |
2014-05-13 |
St. Jude Children's Research Hospital |
Oligonucleotides which inhibit p53 induction in response to cellular stress
|
EP2534489A1
(en)
|
2010-02-10 |
2012-12-19 |
Novartis AG |
Methods and compounds for muscle growth
|
EP2547368A4
(en)
|
2010-03-19 |
2014-08-06 |
Univ South Alabama |
METHOD AND COMPOSITIONS FOR CANCER TREATMENT
|
EP2550001B1
(en)
|
2010-03-24 |
2019-05-22 |
Phio Pharmaceuticals Corp. |
Rna interference in ocular indications
|
WO2011119852A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
WO2011119887A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Pharmaceuticals Corporation |
Rna interference in dermal and fibrotic indications
|
US8455455B1
(en)
|
2010-03-31 |
2013-06-04 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes involved in hemorrhagic fever
|
US9102938B2
(en)
|
2010-04-01 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
2′ and 5′ modified monomers and oligonucleotides
|
WO2011133868A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
WO2011133876A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
WO2011133658A1
(en)
|
2010-04-22 |
2011-10-27 |
Boston Medical Center Corporation |
Compositions and methods for targeting and delivering therapeutics into cells
|
CN103038345B
(zh)
|
2010-04-29 |
2017-07-21 |
Ionis制药公司 |
转甲状腺素蛋白表达的调节
|
EP2563359A1
(en)
|
2010-04-30 |
2013-03-06 |
Allergan, Inc. |
Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
|
AU2011248184B2
(en)
|
2010-05-04 |
2015-12-17 |
Board Of Regents, The University Of Texas System |
Detection and treatment of fibrosis
|
US8563243B2
(en)
*
|
2010-05-12 |
2013-10-22 |
University Of South Carolina |
Methods for affecting homology-directed DNA double stranded break repair
|
EP3388081A1
(en)
|
2010-05-26 |
2018-10-17 |
Selecta Biosciences, Inc. |
Multivalent synthetic nanocarrier vaccines
|
EP2390327A1
(en)
|
2010-05-27 |
2011-11-30 |
Sylentis S.A. |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
DE102010022937A1
(de)
|
2010-06-04 |
2011-12-08 |
Universitätsklinikum Jena |
Zellspezifisch aktivierbare biologisch wirksame Moleküle auf Grundlage von siRNA, Verfahren zu deren Aktivierung sowie Applikationskit zur Verabreichung
|
US20130236968A1
(en)
|
2010-06-21 |
2013-09-12 |
Alnylam Pharmaceuticals, Inc. |
Multifunctional copolymers for nucleic acid delivery
|
WO2011163436A1
(en)
|
2010-06-24 |
2011-12-29 |
Quark Pharmaceuticals, Inc. |
Double stranded rna compounds to rhoa and use thereof
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US20130323269A1
(en)
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
WO2012019132A2
(en)
|
2010-08-06 |
2012-02-09 |
Cell Signaling Technology, Inc. |
Anaplastic lymphoma kinase in kidney cancer
|
US9243246B2
(en)
|
2010-08-24 |
2016-01-26 |
Sirna Therapeutics, Inc. |
Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
|
US8933051B2
(en)
|
2010-09-30 |
2015-01-13 |
University Of Zurich |
Treatment of B-cell lymphoma with microRNA
|
US20140315973A1
(en)
*
|
2010-10-07 |
2014-10-23 |
Agency For Science, Technology And Research |
Parp-1 inhibitors
|
WO2012051491A1
(en)
|
2010-10-14 |
2012-04-19 |
The United States Of America, As Represented By The Secretary National Institutes Of Health |
Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
|
EP2631291B1
(en)
|
2010-10-22 |
2019-05-15 |
OliX Pharmaceuticals, Inc. |
Nucleic acid molecules inducing rna interference, and uses thereof
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
SG190412A1
(en)
|
2010-12-06 |
2013-06-28 |
Quark Pharmaceuticals Inc |
Double stranded oligonucleotide compounds comprising threose modifications
|
US10202615B2
(en)
|
2010-12-10 |
2019-02-12 |
Vanderbilt University |
Mammalian genes involved in toxicity and infection
|
US9617542B2
(en)
*
|
2010-12-14 |
2017-04-11 |
The United States of America, as representd by The Secretary of Agriculture |
Lepidopteran moth control using double-stranded RNA constructs
|
US9623041B2
(en)
|
2010-12-30 |
2017-04-18 |
Cedars-Sinai Medical Center |
Polymalic acid-based nanobiopolymer compositions
|
US20150018408A1
(en)
|
2013-07-10 |
2015-01-15 |
The Regents Of The University Of Michigan |
Therapeutic antibodies and uses thereof
|
EP2663333B8
(en)
|
2011-01-10 |
2020-06-17 |
The Regents Of The University Of Michigan |
Stem cell factor inhibitor
|
WO2012099755A1
(en)
|
2011-01-11 |
2012-07-26 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
DE102011009470A1
(de)
|
2011-01-21 |
2012-08-09 |
Friedrich-Schiller-Universität Jena |
Biologisch wirksame Nukleotid-Moleküle zur gezielten Abtötung von Zellen, Verwendung derselben sowie Applikationskit
|
US9173894B2
(en)
|
2011-02-02 |
2015-11-03 |
Excaliard Pharamaceuticals, Inc. |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
|
MX2013008944A
(es)
|
2011-02-03 |
2014-01-08 |
Mirna Therapeutics Inc |
Mimeticos sinteticos de mir-124.
|
US9796979B2
(en)
|
2011-03-03 |
2017-10-24 |
Quark Pharmaceuticals Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
CA2828544A1
(en)
*
|
2011-03-03 |
2012-09-07 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
US9233121B2
(en)
*
|
2011-03-11 |
2016-01-12 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for the treatment of cancer
|
BR112013023724A2
(pt)
|
2011-03-15 |
2019-09-24 |
Univ Utah Res Found |
métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento
|
WO2012135696A2
(en)
*
|
2011-04-01 |
2012-10-04 |
University Of South Alabama |
Methods and compositions for the diagnosis, classification, and treatment of cancer
|
EP2686342A2
(en)
|
2011-04-12 |
2014-01-22 |
The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services |
Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
|
AU2012242642A1
(en)
|
2011-04-13 |
2013-05-02 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
AU2012242455A1
(en)
*
|
2011-04-15 |
2013-11-28 |
Molecular Transfer, Inc. |
Agents for improved delivery of nucleic acids to eukaryotic cells
|
US8716257B2
(en)
*
|
2011-04-15 |
2014-05-06 |
Sutter West Bay Hospitals |
CMV gene products promote cancer stem cell growth
|
AU2012259312A1
(en)
|
2011-05-20 |
2013-12-12 |
Government Of The United States, As Represented By The Secretary Department Of Health And Human Services |
Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
|
WO2012167173A1
(en)
|
2011-06-02 |
2012-12-06 |
The University Of Louisville Research Foundation, Inc. |
Anti-nucleolin agent-conjugated nanoparticles
|
JP6236385B2
(ja)
|
2011-06-21 |
2017-11-22 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アポリポタンパク質c−iii(apoc3)の発現を阻害するための組成物及び方法
|
EP2723861A4
(en)
|
2011-06-21 |
2014-12-10 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
EP2723758B1
(en)
|
2011-06-21 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
WO2013001372A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of Oslo |
Methods and compositions for inhibition of activation of regulatory t cells
|
JP2014520792A
(ja)
|
2011-07-06 |
2014-08-25 |
スィーケフス ソールラン ホーエフ |
Egfr標的治療
|
WO2013006861A1
(en)
|
2011-07-07 |
2013-01-10 |
University Of Georgia Research Foundation, Inc. |
Sorghum grain shattering gene and uses thereof in altering seed dispersal
|
US8853181B2
(en)
|
2011-07-21 |
2014-10-07 |
Albert Einstein College Of Medicine Of Yeshiva University |
Fidgetin-like 2 as a target to enhance wound healing
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
DE102011118024A1
(de)
|
2011-08-01 |
2013-02-07 |
Technische Universität Dresden |
Inhibitor der Expression der Pro-Caspase 1
|
US9388411B2
(en)
|
2011-09-06 |
2016-07-12 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. |
miRNA-212/132 family as a therapeutic target
|
US8865188B2
(en)
|
2011-09-09 |
2014-10-21 |
Biomed Realty, L.P. |
Methods and compositions for controlling assembly of viral proteins
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
US9951349B2
(en)
|
2011-09-27 |
2018-04-24 |
Yale University |
Compositions and methods for transient expression of recombinant RNA
|
JP6250543B2
(ja)
|
2011-09-27 |
2017-12-20 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
ジ脂肪族置換peg化脂質
|
CN103987847B
(zh)
|
2011-10-18 |
2017-06-16 |
迪克纳制药公司 |
胺阳离子脂质及其用途
|
US20140323549A1
(en)
|
2011-11-08 |
2014-10-30 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
US9006199B2
(en)
*
|
2011-11-14 |
2015-04-14 |
Silenseed Ltd. |
Methods and compositions for treating prostate cancer
|
IL284530B
(en)
|
2011-11-18 |
2022-07-01 |
Alnylam Pharmaceuticals Inc |
rnai factors, preparations and methods of using them for the treatment of transthyretin-related diseases
|
WO2013082529A1
(en)
|
2011-12-02 |
2013-06-06 |
Yale University |
Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
|
JP2015509085A
(ja)
|
2012-01-01 |
2015-03-26 |
キュービーアイ エンタープライゼズ リミテッドQbi Enterprises Ltd. |
治療剤および診断剤の選択的送達のためのendo180を標的とする粒子
|
US9464291B2
(en)
*
|
2012-01-06 |
2016-10-11 |
University Of South Alabama |
Methods and compositions for the treatment of cancer
|
US10023862B2
(en)
|
2012-01-09 |
2018-07-17 |
Arrowhead Pharmaceuticals, Inc. |
Organic compositions to treat beta-catenin-related diseases
|
JP2016528161A
(ja)
|
2012-01-12 |
2016-09-15 |
クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. |
聴覚およびバランス障害を治療するための併用療法
|
US20150126438A1
(en)
|
2012-01-24 |
2015-05-07 |
Beth Israel Deaconess Medical Center, Inc. |
Novel ChREBP Isoforms and Methods Using the Same
|
EP2825210B1
(en)
|
2012-03-14 |
2019-06-26 |
University of Central Florida Research Foundation, Inc. |
Lim kinasemodulating agents for neurofibromatoses therapy and methods for screening for same
|
EP2825648B1
(en)
|
2012-03-15 |
2018-09-05 |
CuRNA, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
US20150056193A1
(en)
|
2012-04-18 |
2015-02-26 |
Cell Signaling Technology, Inc. |
Egfr and ros1 kinase in cancer
|
US9980942B2
(en)
|
2012-05-02 |
2018-05-29 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
CN104755620B
(zh)
|
2012-05-22 |
2018-03-02 |
奥利克斯医药有限公司 |
具有细胞内穿透能力的诱导rna干扰的核酸分子及其用途
|
EP2867368B1
(en)
|
2012-07-06 |
2022-01-12 |
Institut Gustave Roussy |
Simultaneous detection of cannibalism and senescence as prognostic marker for cancer
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
EP3441467A3
(en)
|
2012-08-31 |
2019-04-24 |
The General Hospital Corporation |
Biotin complexes for treatment and diagnosis of alzheimer's disease
|
MX368084B
(es)
|
2012-09-05 |
2019-09-19 |
Sylentis Sau |
siRNA Y SU USO EN LA PREPARACIÓN DE UN MEDICAMENTO PARA USARSE EN UN MÉTODO PARA EL TRATAMIENTO DE UN TRANSTORNO OCULAR.
|
GB201215857D0
(en)
|
2012-09-05 |
2012-10-24 |
Sylentis Sau |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
WO2014043292A1
(en)
|
2012-09-12 |
2014-03-20 |
Quark Pharmaceuticals, Inc. |
Double-stranded oligonucleotide molecules to p53 and methods of use thereof
|
US9611474B2
(en)
|
2012-09-12 |
2017-04-04 |
Quark Pharmaceuticals, Inc. |
Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof
|
BR112015006176B1
(pt)
|
2012-09-21 |
2023-04-18 |
Intensity Therapeutics, Inc |
Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular
|
EP3795694A3
(en)
*
|
2012-10-02 |
2021-06-23 |
The General Hospital Corporation d/b/a Massachusetts General Hospital |
Methods relating to dna-sensing pathway related conditions
|
WO2014055825A1
(en)
|
2012-10-04 |
2014-04-10 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
A formulation of mycobacterial components as an adjuvant for inducing th17 responses
|
WO2014068072A1
(en)
|
2012-10-31 |
2014-05-08 |
Institut Gustave-Roussy |
Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
|
EP3415627A1
(en)
*
|
2012-11-13 |
2018-12-19 |
Codiak BioSciences, Inc. |
Delivery of therapeutic agent
|
DE102012022596B4
(de)
|
2012-11-15 |
2017-05-04 |
Friedrich-Schiller-Universität Jena |
Neue zellspezifisch wirksame Nukleotid-Moleküle und Applikationskit zu deren Anwendung
|
JP2016505527A
(ja)
|
2012-11-15 |
2016-02-25 |
アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. |
細胞反応性、長時間作用型または標的化コンプスタチン類似体ならびに関係する組成物および方法
|
DK3502240T3
(da)
|
2012-11-27 |
2021-08-09 |
Childrens Medical Ct Corp |
Målretning af distale bcl11a-reguleringselementer til føtal hæmoglobinreinduktion
|
WO2014093688A1
(en)
|
2012-12-12 |
2014-06-19 |
1Massachusetts Institute Of Technology |
Compositions and methods for functional nucleic acid delivery
|
WO2014095088A1
(en)
|
2012-12-21 |
2014-06-26 |
Sykehuset Sørlandet Hf |
Egfr targeted therapy of neurological disorders and pain
|
US9206423B2
(en)
*
|
2012-12-30 |
2015-12-08 |
The Regents Of The University Of California |
Methods of modulating compliance of the trabecular meshwork
|
WO2014113541A1
(en)
|
2013-01-16 |
2014-07-24 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Attenuated chlamydia vaccine
|
DE102013003869B4
(de)
|
2013-02-27 |
2016-11-24 |
Friedrich-Schiller-Universität Jena |
Verfahren zur gezielten Abtötung von Zellen durch zur mRNA-Anbindung ausgerichtete Nukleotid-Moleküle sowie Nukleotid-Moleküle und Applikationskit für solche Verwendung
|
CA3120574A1
(en)
|
2013-03-14 |
2014-09-25 |
Dicerna Pharmaceuticals, Inc. |
Process for formulating an anionic agent
|
KR20150132198A
(ko)
*
|
2013-03-15 |
2015-11-25 |
제넨테크, 인크. |
브로모도메인-함유 단백질 brd7 및 brd9의 억제에 의한 th2-매개 질환의 치료
|
US9850543B2
(en)
*
|
2013-03-15 |
2017-12-26 |
Novartis Ag |
Biomarkers associated with BRM inhibition
|
US10308687B2
(en)
|
2013-03-15 |
2019-06-04 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
EP3708184A1
(en)
|
2013-03-27 |
2020-09-16 |
The General Hospital Corporation |
Methods and agents for treating alzheimer s disease
|
WO2014186798A1
(en)
|
2013-05-17 |
2014-11-20 |
Amplimmune, Inc. |
Receptors for b7-h4
|
US10220053B2
(en)
|
2013-06-25 |
2019-03-05 |
University Of Canberra |
Methods and compositions for modulating cancer stem cells
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
WO2015010026A2
(en)
|
2013-07-19 |
2015-01-22 |
Monsanto Technology Llc |
Compositions and methods for controlling leptinotarsa
|
US10711106B2
(en)
|
2013-07-25 |
2020-07-14 |
The University Of Chicago |
High aspect ratio nanofibril materials
|
EP3027223A1
(en)
|
2013-07-31 |
2016-06-08 |
QBI Enterprises Ltd. |
Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
|
US9889200B2
(en)
|
2013-07-31 |
2018-02-13 |
Qbi Enterprises Ltd. |
Sphingolipid-polyalkylamine-oligonucleotide compounds
|
EP3715457A3
(en)
*
|
2013-08-28 |
2020-12-16 |
Ionis Pharmaceuticals, Inc. |
Modulation of prekallikrein (pkk) expression
|
WO2015038811A2
(en)
|
2013-09-11 |
2015-03-19 |
Arsia Therapeutics, Inc. |
Liquid protein formulations containing ionic liquids
|
CN105764513A
(zh)
|
2013-09-18 |
2016-07-13 |
堪培拉大学 |
干细胞调控ii
|
WO2015051045A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE
|
JP6546161B2
(ja)
|
2013-10-04 |
2019-07-17 |
ノバルティス アーゲー |
B型肝炎ウイルスを治療するための有機化合物
|
EP2865756A1
(en)
|
2013-10-22 |
2015-04-29 |
Sylentis, S.A.U. |
siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene.
|
EP2865758A1
(en)
|
2013-10-22 |
2015-04-29 |
Sylentis, S.A.U. |
siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
|
EP2865757A1
(en)
|
2013-10-22 |
2015-04-29 |
Sylentis, S.A.U. |
siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene.
|
US10004814B2
(en)
|
2013-11-11 |
2018-06-26 |
Sirna Therapeutics, Inc. |
Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
|
EP3071590A4
(en)
|
2013-11-21 |
2017-07-19 |
SeNA Research, Inc. |
Methods for structural determination of selenium derivatized nucleic acid complexes
|
RU2744194C2
(ru)
|
2013-12-02 |
2021-03-03 |
Фио Фармасьютикалс Корп |
Иммунотерапия рака
|
WO2015085158A1
(en)
|
2013-12-06 |
2015-06-11 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of transthyretin (ttr) by double-stranded rna
|
CN104830906B
(zh)
|
2014-02-12 |
2018-09-04 |
北京维通达生物技术有限公司 |
一种重编程获得功能性人肝脏实质细胞的方法
|
US10011837B2
(en)
|
2014-03-04 |
2018-07-03 |
Sylentis Sau |
SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
EP3116902B1
(en)
|
2014-03-11 |
2020-01-01 |
Cellectis |
Method for generating t-cells compatible for allogenic transplantation
|
DK3119887T3
(da)
*
|
2014-03-20 |
2019-05-20 |
Oommen Varghese |
Forbedrede korte interfererende ribonukleinsyremolekyler
|
JP6771387B2
(ja)
|
2014-03-25 |
2020-10-21 |
アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. |
遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的unaオリゴマー
|
US9856475B2
(en)
|
2014-03-25 |
2018-01-02 |
Arcturus Therapeutics, Inc. |
Formulations for treating amyloidosis
|
JP6752151B2
(ja)
|
2014-03-25 |
2020-09-09 |
アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. |
遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー
|
CN106413390B
(zh)
|
2014-04-01 |
2019-09-27 |
孟山都技术公司 |
用于控制虫害的组合物和方法
|
HRP20220798T1
(hr)
|
2014-04-01 |
2022-10-14 |
Biogen Ma Inc. |
Pripravci za modulaciju ekspresije sod-1
|
ES2744186T3
(es)
|
2014-04-25 |
2020-02-24 |
Childrens Medical Center |
Composiciones y métodos para tratar las hemoglobinopatías
|
US11279934B2
(en)
|
2014-04-28 |
2022-03-22 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
|
EP3862362A3
(en)
|
2014-05-01 |
2021-10-27 |
Ionis Pharmaceuticals, Inc. |
Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
|
WO2015168674A1
(en)
|
2014-05-02 |
2015-11-05 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for anti-lyst immunomodulation
|
US10335500B2
(en)
|
2014-05-12 |
2019-07-02 |
The Johns Hopkins University |
Highly stable biodegradable gene vector platforms for overcoming biological barriers
|
CA2948844C
(en)
|
2014-05-12 |
2020-06-30 |
The Johns Hopkins University |
Engineering synthetic brain penetrating gene vectors
|
WO2015184105A1
(en)
|
2014-05-29 |
2015-12-03 |
Trustees Of Dartmouth College |
Method for selectively inhibiting acat1 in the treatment of neurodegenerative diseases
|
US10434064B2
(en)
|
2014-06-04 |
2019-10-08 |
Exicure, Inc. |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
CN104120127B
(zh)
*
|
2014-07-01 |
2016-09-21 |
清华大学 |
分离的寡核苷酸及其应用
|
US10378012B2
(en)
|
2014-07-29 |
2019-08-13 |
Monsanto Technology Llc |
Compositions and methods for controlling insect pests
|
WO2016019126A1
(en)
|
2014-07-30 |
2016-02-04 |
The Research Foundation For The State University Of New York |
System and method for delivering genetic material or protein to cells
|
WO2016023974A1
(de)
|
2014-08-14 |
2016-02-18 |
Friedrich-Schiller-Universität Jena |
Peptid zur verwendung in der reduktion von nebenwirkungen in form von immunstimulatorischen reaktionen/effekten
|
US10485772B2
(en)
|
2014-08-25 |
2019-11-26 |
EpiAxis Therapeutics Pty Ltd. |
Compositions for modulating cancer stem cells and uses therefor
|
KR20220087571A
(ko)
|
2014-08-29 |
2022-06-24 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법
|
KR102506169B1
(ko)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
EP3194581A4
(en)
|
2014-09-15 |
2018-04-25 |
Children's Medical Center Corporation |
Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
|
CA2962406A1
(en)
|
2014-09-25 |
2016-03-31 |
Cold Spring Harbor Laboratory |
Treatment of rett syndrome
|
JP6716577B2
(ja)
|
2014-10-01 |
2020-07-01 |
イーグル・バイオロジクス・インコーポレイテッドEagle Biologics, Inc. |
粘度低下物質を含有する、多糖および核酸の調合薬
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
AU2015330731B2
(en)
|
2014-10-10 |
2020-07-09 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using TLR9 agonist with checkpoint inhibitors
|
US10538762B2
(en)
*
|
2014-10-14 |
2020-01-21 |
The Board Of Regents Of The University Of Texas System |
Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAS targeting the expanded hexanucleotide repeat
|
EP3209794A1
(en)
|
2014-10-22 |
2017-08-30 |
Katholieke Universiteit Leuven KU Leuven Research & Development |
Modulating adipose tissue and adipogenesis
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
UA124449C2
(uk)
|
2014-11-12 |
2021-09-22 |
Нмк, Інк. |
Трансгенна рослина з модифікованою редокс-залежною модуляцією пігментів фотосинтетичних антенних комплексів та спосіб її одержання
|
WO2016081444A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
WO2016081621A1
(en)
|
2014-11-18 |
2016-05-26 |
Yale University |
Formulations for targeted release of agents under low ph conditions and methods of use thereof
|
CN107106493A
(zh)
|
2014-11-21 |
2017-08-29 |
西北大学 |
球形核酸纳米颗粒缀合物的序列特异性细胞摄取
|
US20190002876A1
(en)
*
|
2014-12-09 |
2019-01-03 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treatment of friedreich's ataxia
|
US10264976B2
(en)
|
2014-12-26 |
2019-04-23 |
The University Of Akron |
Biocompatible flavonoid compounds for organelle and cell imaging
|
US10792299B2
(en)
|
2014-12-26 |
2020-10-06 |
Nitto Denko Corporation |
Methods and compositions for treating malignant tumors associated with kras mutation
|
US20180002702A1
(en)
*
|
2014-12-26 |
2018-01-04 |
Nitto Denko Corporation |
Methods and compositions for treating malignant tumors associated with kras mutation
|
JP6942632B2
(ja)
|
2015-01-22 |
2021-09-29 |
モンサント テクノロジー エルエルシー |
Leptinotarsa防除用組成物及びその方法
|
US10519447B2
(en)
|
2015-04-01 |
2019-12-31 |
Arcturus Therapeutics, Inc. |
Therapeutic UNA oligomers and uses thereof
|
EA201792263A1
(ru)
|
2015-04-13 |
2018-08-31 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
US20180126014A1
(en)
|
2015-04-15 |
2018-05-10 |
Yale University |
Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
|
WO2016179394A1
(en)
|
2015-05-05 |
2016-11-10 |
Malik Mohammad Tariq |
Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
|
JP7288302B2
(ja)
|
2015-05-08 |
2023-06-07 |
ザ チルドレンズ メディカル センター コーポレーション |
胎児型ヘモグロビン再誘導のための、bcl11aエンハンサー機能性領域を標的とする方法
|
EP3302710A4
(en)
|
2015-06-03 |
2019-02-20 |
The University of Queensland |
MOBILIZERS AND USE THEREOF
|
AU2016275046B2
(en)
|
2015-06-10 |
2022-07-28 |
Board Of Regents, The University Of Texas System |
Use of exosomes for the treatment of disease
|
WO2017002928A1
(ja)
|
2015-06-30 |
2017-01-05 |
岸本 忠三 |
新規な肺疾患治療剤および/またはそのスクリーニング方法
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
KR20180026739A
(ko)
|
2015-07-06 |
2018-03-13 |
알엑스아이 파마슈티칼스 코포레이션 |
슈퍼옥시드 디스뮤타제 1 (sod1)을 표적화하는 핵산 분자
|
CA2991894A1
(en)
|
2015-07-10 |
2017-01-19 |
Ionis Pharmaceuticals, Inc. |
Modulators of diacyglycerol acyltransferase 2 (dgat2)
|
WO2017015671A1
(en)
|
2015-07-23 |
2017-01-26 |
Arcturus Therapeutics, Inc. |
Compositions for treating amyloidosis
|
UA126276C2
(uk)
|
2015-07-31 |
2022-09-14 |
Елнілем Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ НА ОСНОВІ iRNA ДЛЯ ТРАНСТИРЕТИНУ (TTR) І СПОСІБ ЇЇ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ АБО ПОПЕРЕДЖЕННЯ TTR-АСОЦІЙОВАНОГО ЗАХВОРЮВАННЯ
|
CN108366966A
(zh)
|
2015-08-24 |
2018-08-03 |
光环生物干扰疗法公司 |
用于调节基因表达的多核苷酸纳米颗粒及其用途
|
MA44908A
(fr)
|
2015-09-08 |
2018-07-18 |
Sylentis Sau |
Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp
|
GB201516685D0
(en)
*
|
2015-09-21 |
2015-11-04 |
Varghese Oommen P And Oommen Oommen P |
Nucleic acid molecules with enhanced activity
|
US10383935B2
(en)
|
2015-09-23 |
2019-08-20 |
Regents Of The University Of Minnesota |
Methods of making and using live attenuated viruses
|
CN108601823A
(zh)
|
2015-09-23 |
2018-09-28 |
麻省理工学院 |
用于改性树枝状聚合物纳米颗粒疫苗递送的组合物和方法
|
US10086063B2
(en)
|
2015-09-23 |
2018-10-02 |
Regents Of The University Of Minnesota |
Methods of making and using live attenuated viruses
|
AU2016332900C1
(en)
|
2015-09-29 |
2024-02-01 |
Amgen Inc. |
ASGR inhibitors
|
JOP20210043A1
(ar)
*
|
2015-10-01 |
2017-06-16 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
EP4349363A2
(en)
|
2015-10-07 |
2024-04-10 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens
|
EP3365446A4
(en)
|
2015-10-19 |
2019-06-26 |
Phio Pharmaceuticals Corp. |
SELF ADMINISTRATION-REDUCED SIZE NUCLEIC ACID COMPOUNDS TARGETING LONGS NON-CODING LONGS
|
EP3377630A4
(en)
|
2015-11-16 |
2020-01-01 |
Olix Pharmaceuticals, Inc. |
TREATMENT OF AGE-RELATED MACULAR DEGENERATION USING RNA COMPLEXES THAT TARGET MYD88 OR TLR3
|
WO2017095751A1
(en)
|
2015-12-02 |
2017-06-08 |
Partikula Llc |
Compositions and methods for modulating cancer cell metabolism
|
EP3386544B1
(en)
|
2015-12-10 |
2020-11-25 |
Fibrogen, Inc. |
Methods for treatment of motor neuron diseases
|
NZ743320A
(en)
|
2015-12-18 |
2019-03-29 |
Samyang Biopharmaceuticals |
Method for preparing polymeric micelle containing anionic drug
|
BR102017001164A2
(pt)
|
2016-01-26 |
2019-03-06 |
Embrapa - Empresa Brasileira De Pesquisa Agropecuária |
Composições de rna de fita dupla para controle de diaphorina citri e métodos de uso.
|
WO2017132669A1
(en)
|
2016-01-31 |
2017-08-03 |
University Of Massachusetts |
Branched oligonucleotides
|
KR20180104692A
(ko)
|
2016-02-02 |
2018-09-21 |
올릭스 주식회사 |
Angpt2 및 pdgfb를 표적화하는 rna 복합체를 사용하는 혈관신생 관련 질환의 치료
|
CN108779463B
(zh)
|
2016-02-02 |
2022-05-24 |
奥利克斯医药有限公司 |
使用靶向IL4Rα、TRPA1或F2RL1的RNA复合物治疗特应性皮炎和哮喘
|
US20170246262A1
(en)
|
2016-02-25 |
2017-08-31 |
Applied Biological Laboratories, Inc. |
Compositions and methods for protecting against airborne pathogens and irritants
|
US20170360815A1
(en)
|
2016-02-25 |
2017-12-21 |
Applied Biological Laboratories, Inc. |
Compositions and methods for protecting against airborne pathogens and irritants
|
WO2017147594A1
(en)
|
2016-02-26 |
2017-08-31 |
Yale University |
COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS
|
US20210189062A1
(en)
|
2016-03-01 |
2021-06-24 |
Alexion Pharmaceuticals, Inc. |
Biodegradable activated polymers for therapeutic delivery
|
EP3423568A4
(en)
|
2016-03-04 |
2019-11-13 |
University Of Louisville Research Foundation, Inc. |
METHOD AND COMPOSITIONS FOR EX-VIVO REPRODUCTION OF VERY SMALL EMBRYONAL STEM CELLS (VSELS)
|
CA3011946A1
(en)
|
2016-03-07 |
2017-09-14 |
Arrowhead Pharmaceuticals, Inc. |
Targeting ligands for therapeutic compounds
|
AU2017234163B2
(en)
|
2016-03-15 |
2023-01-19 |
Mersana Therapeutics, Inc. |
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
MA45469A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de bêta-caténine et leurs utilisations
|
MA45470A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques kras et leurs utilisations
|
US20190117799A1
(en)
|
2016-04-01 |
2019-04-25 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
MA45349A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques egfr et leurs utilisations
|
CN108602849B
(zh)
|
2016-04-06 |
2022-10-21 |
俄亥俄州国家创新基金会 |
用于通过rna纳米技术将治疗剂特异性递送至细胞的rna配体展示外来体
|
CA3020487C
(en)
|
2016-04-11 |
2022-05-31 |
Olix Pharmaceuticals, Inc. |
Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
|
NZ747314A
(en)
|
2016-04-14 |
2022-07-29 |
Benitec Ip Holdings Inc |
Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof
|
US11410746B2
(en)
|
2016-04-27 |
2022-08-09 |
Massachusetts Institute Of Technology |
Stable nanoscale nucleic acid assemblies and methods thereof
|
WO2017197128A1
(en)
|
2016-05-11 |
2017-11-16 |
Yale University |
Poly(amine-co-ester) nanoparticles and methods of use thereof
|
KR101916652B1
(ko)
|
2016-06-29 |
2018-11-08 |
올릭스 주식회사 |
작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
|
CN109983121A
(zh)
|
2016-06-30 |
2019-07-05 |
昂克诺斯公司 |
治疗性多肽的假型化溶瘤病毒递送
|
RU2627179C1
(ru)
*
|
2016-07-28 |
2017-08-03 |
федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации |
ТЕСТ-СИСТЕМА ДЛЯ ОПРЕДЕЛЕНИЯ РНК ИНТЕРФЕРОНА λ, ИНТЕРЛЕЙКИНА IL23 И ПРОТИВОВИРУСНОГО БЕЛКА MxA
|
WO2018020012A1
(en)
|
2016-07-29 |
2018-02-01 |
Danmarks Tekniske Universitet |
Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides
|
JP2019524787A
(ja)
|
2016-08-03 |
2019-09-05 |
エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド |
Tlr9標的治療薬
|
WO2018039629A2
(en)
|
2016-08-25 |
2018-03-01 |
Northwestern University |
Micellar spherical nucleic acids from thermoresponsive, traceless templates
|
TW202320855A
(zh)
|
2016-09-02 |
2023-06-01 |
美商愛羅海德製藥公司 |
標靶性配體
|
KR102350647B1
(ko)
|
2016-09-02 |
2022-01-14 |
다이서나 파마수이티컬, 인크. |
4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드
|
WO2018057575A1
(en)
|
2016-09-21 |
2018-03-29 |
Alnylam Pharmaceuticals, Inc |
Myostatin irna compositions and methods of use thereof
|
US11260134B2
(en)
|
2016-09-29 |
2022-03-01 |
National University Corporation Tokyo Medical And Dental University |
Double-stranded nucleic acid complex having overhang
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
EP3551641A4
(en)
|
2016-12-08 |
2021-01-13 |
University of Utah Research Foundation |
STAUFEN1 ACTIVE SUBSTANCES AND RELATED PROCEDURES
|
US20200085758A1
(en)
|
2016-12-16 |
2020-03-19 |
The Brigham And Women's Hospital, Inc. |
Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
|
BR112019014282A2
(pt)
|
2017-01-10 |
2020-03-03 |
Arrowhead Pharmaceuticals, Inc. |
Agentes de rnai de antitripsina (aat) alfa-1, composições incluindo agentes de rnai de aat, e métodos de uso
|
CN110770343A
(zh)
*
|
2017-02-10 |
2020-02-07 |
成均馆大学校产学协力团 |
用于rna干扰的长双链rna
|
WO2018152524A1
(en)
*
|
2017-02-20 |
2018-08-23 |
Northwestern University |
Toxic rnai active seed sequences for killing cancer cells
|
DE102017103383A1
(de)
|
2017-02-20 |
2018-08-23 |
aReNA-Bio GbR (vertretungsberechtigter Gesellschafter: Dr. Heribert Bohlen, 50733 Köln) |
System und Verfahren zur Zelltyp-spezifischen Translation von RNA-Molekülen in Eukaryoten
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
US11261441B2
(en)
|
2017-03-29 |
2022-03-01 |
Bluebird Bio, Inc. |
Vectors and compositions for treating hemoglobinopathies
|
CN110831544B
(zh)
|
2017-04-07 |
2022-11-18 |
阿佩利斯制药有限公司 |
长效坎普他汀类似物、其组合物的给药方案及其医药用途
|
EP3610018B1
(en)
|
2017-04-14 |
2023-06-07 |
Arizona Board of Regents on Behalf of the University of Arizona |
Compositions and methods for treating pulmonary fibrosis
|
US11324820B2
(en)
|
2017-04-18 |
2022-05-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
|
WO2018209270A1
(en)
|
2017-05-11 |
2018-11-15 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (snas)
|
US11788087B2
(en)
|
2017-05-25 |
2023-10-17 |
The Children's Medical Center Corporation |
BCL11A guide delivery
|
JP7406793B2
(ja)
*
|
2017-06-23 |
2023-12-28 |
ユニバーシティー オブ マサチューセッツ |
2テイル自己デリバリー型siRNAおよび関連方法
|
KR20200024793A
(ko)
|
2017-07-06 |
2020-03-09 |
애로우헤드 파마슈티컬스 인코포레이티드 |
알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
|
WO2019014491A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals, Inc. |
METHODS OF INHIBITING GENE EXPRESSION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE))
|
US11104700B2
(en)
|
2017-07-17 |
2021-08-31 |
Oxford University Innovation Limited |
Oligonucleotides
|
US11110114B2
(en)
|
2017-07-17 |
2021-09-07 |
Oxford University Innovation Limited |
Dinucleotides
|
CA3074303A1
(en)
|
2017-09-11 |
2019-03-14 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
|
AU2018336806A1
(en)
|
2017-09-19 |
2020-05-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
|
WO2019068326A1
(en)
|
2017-10-05 |
2019-04-11 |
Université D'aix-Marseille |
INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
|
LT3684377T
(lt)
|
2017-10-20 |
2023-03-10 |
Dicerna Pharmaceuticals, Inc. |
Hepatito b infekcijos gydymo būdai
|
WO2019100053A1
(en)
|
2017-11-20 |
2019-05-23 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for modulating hif-2α to improve muscle generation and repair
|
US11638760B2
(en)
|
2017-11-27 |
2023-05-02 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
CN111433361B
(zh)
*
|
2017-12-01 |
2024-03-29 |
德克萨斯A&M大学体系 |
天使综合征反义治疗
|
KR102443358B1
(ko)
|
2017-12-06 |
2022-09-14 |
어비디티 바이오사이언시스 인크. |
근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
|
EP3728281A1
(en)
|
2017-12-21 |
2020-10-28 |
Alnylam Pharmaceuticals Inc. |
Chirally-enriched double-stranded rna agents
|
CN111757757A
(zh)
|
2017-12-21 |
2020-10-09 |
梅尔莎纳医疗公司 |
吡咯并苯并二氮呯抗体共轭物
|
US10960086B2
(en)
|
2017-12-28 |
2021-03-30 |
Augusta University Research Institute, Inc. |
Aptamer compositions and methods of use thereof
|
EP3731850A4
(en)
|
2017-12-29 |
2021-12-01 |
Oncorus, Inc. |
ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
|
WO2019136157A2
(en)
|
2018-01-05 |
2019-07-11 |
Dicerna Pharmaceuticals, Inc. |
Reducing beta-catenin and ido expression to potentiate immunotherapy
|
MX2020007582A
(es)
|
2018-01-16 |
2020-09-03 |
Dicerna Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion de aldehido deshidrogenasa mitocondrial 2 (aldh2).
|
MA51795A
(fr)
|
2018-02-09 |
2020-12-16 |
Hoffmann La Roche |
Oligonucléotides pour moduler l'expression de tmem106b
|
US20220002796A1
(en)
|
2018-05-07 |
2022-01-06 |
Roche Innovation Center Copenhagen A/S |
Quality control of lna oligonucleotide therapeutics using massively parallel sequencing
|
EP3791180A1
(en)
|
2018-05-10 |
2021-03-17 |
The University Of Manchester |
Methods for assessing macular degeneration
|
US11946046B2
(en)
*
|
2018-06-14 |
2024-04-02 |
University Of Utah Research Foundation |
Staufen1 regulating agents and associated methods
|
JP2021533767A
(ja)
|
2018-08-13 |
2021-12-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
B型肝炎ウイルス(HBV)dsRNA物質組成物およびその使用方法
|
EP3846797A4
(en)
|
2018-09-04 |
2022-06-08 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
USE OF DELTA-TOCOTRIENOL FOR THE TREATMENT OF CANCER
|
US20210317479A1
(en)
|
2018-09-06 |
2021-10-14 |
The Broad Institute, Inc. |
Nucleic acid assemblies for use in targeted delivery
|
US20230021500A1
(en)
|
2018-10-29 |
2023-01-26 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
BR112021015651A2
(pt)
|
2019-02-12 |
2021-10-05 |
Dicerna Pharmaceuticals, Inc. |
Métodos e composições para inibir a expressão de cyp27a1
|
AU2020253823A1
(en)
|
2019-03-29 |
2021-10-14 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for the treatment of KRAS associated diseases or disorders
|
EP3947683A1
(en)
|
2019-04-04 |
2022-02-09 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting gene expression in the central nervous system
|
US11814464B2
(en)
|
2019-04-29 |
2023-11-14 |
Yale University |
Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
|
CN113795581A
(zh)
|
2019-05-03 |
2021-12-14 |
迪克纳制药公司 |
具有缩短的有义链的双链核酸抑制剂分子
|
US20200369759A1
(en)
|
2019-05-23 |
2020-11-26 |
Fibrogen, Inc. |
Methods of treatment of muscular dystrophies
|
EP3990028A4
(en)
|
2019-06-26 |
2023-08-09 |
Biorchestra Co., Ltd. |
MICELLAR NANOPARTICLES AND ASSOCIATED USES
|
US20230227583A1
(en)
|
2019-08-30 |
2023-07-20 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
TW202123973A
(zh)
|
2019-09-10 |
2021-07-01 |
日商第一三共股份有限公司 |
用於肝臟遞送之GalNAc-寡核苷酸結合物及製造方法
|
KR20220069103A
(ko)
|
2019-10-02 |
2022-05-26 |
다이서나 파마수이티컬, 인크. |
최소 플루오린 함량을 갖는 작은 간섭 rna의 화학적 변형
|
US11017851B1
(en)
|
2019-11-26 |
2021-05-25 |
Cypress Semiconductor Corporation |
Silicon-oxide-nitride-oxide-silicon based multi level non-volatile memory device and methods of operation thereof
|
JP2023509872A
(ja)
|
2019-12-24 |
2023-03-10 |
エフ. ホフマン-ラ ロシュ アーゲー |
Hbvを標的とする抗ウイルス剤及び/又はhbvの処置のための免疫調節剤の医薬組合せ
|
AU2020410993A1
(en)
|
2019-12-24 |
2022-06-16 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
IL294388A
(en)
|
2020-01-14 |
2022-08-01 |
Synthekine Inc |
il2 orthologs and methods of use
|
WO2021150300A1
(en)
|
2020-01-22 |
2021-07-29 |
Massachusetts Institute Of Technology |
Inducible tissue constructs and uses thereof
|
US11642407B2
(en)
|
2020-02-28 |
2023-05-09 |
Massachusetts Institute Of Technology |
Identification of variable influenza residues and uses thereof
|
MX2022011550A
(es)
|
2020-03-18 |
2023-01-04 |
Dicerna Pharmaceuticals Inc |
Composiciones y métodos para inhibir la expresión de angptl3.
|
JP2023537798A
(ja)
|
2020-03-19 |
2023-09-06 |
アビディティー バイオサイエンシーズ,インク. |
顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
|
EP4126066A4
(en)
|
2020-03-27 |
2024-04-24 |
Avidity Biosciences Inc |
COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHY
|
TW202206592A
(zh)
|
2020-04-22 |
2022-02-16 |
美商艾歐凡斯生物治療公司 |
用於協調產製供病患特異性免疫治療之細胞的系統和方法
|
WO2021255262A1
(en)
|
2020-06-19 |
2021-12-23 |
Sylentis Sau |
siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
|
CA3183351A1
(en)
|
2020-06-19 |
2021-12-23 |
Yale University |
Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
|
US20220031633A1
(en)
|
2020-07-28 |
2022-02-03 |
Yale University |
Poly(amine-co-ester) polymeric particles for selective pulmonary delivery
|
EP4192505A1
(en)
|
2020-08-04 |
2023-06-14 |
Dicerna Pharmaceuticals, Inc. |
Systemic delivery of oligonucleotides
|
MX2023001450A
(es)
|
2020-08-04 |
2023-04-14 |
Dicerna Pharmaceuticals Inc |
Composiciones y metodos para la inhibicion de la expresion de plp1.
|
TW202221120A
(zh)
|
2020-08-04 |
2022-06-01 |
美商黛瑟納製藥公司 |
用於治療代謝症候群之組成物及方法
|
KR20230043912A
(ko)
|
2020-08-05 |
2023-03-31 |
다이서나 파마수이티컬, 인크. |
Lpa 발현을 저해하기 위한 조성물 및 방법
|
WO2022029209A1
(en)
|
2020-08-05 |
2022-02-10 |
F. Hoffmann-La Roche Ag |
Oligonucleotide treatment of hepatitis b patients
|
WO2022047424A1
(en)
|
2020-08-31 |
2022-03-03 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
EP3964204A1
(en)
|
2020-09-08 |
2022-03-09 |
Université d'Aix-Marseille |
Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
|
EP4214515A1
(en)
|
2020-09-16 |
2023-07-26 |
Complement Therapeutics Limited |
Complementome assay
|
WO2022115645A1
(en)
|
2020-11-25 |
2022-06-02 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
CN117295753A
(zh)
|
2020-12-04 |
2023-12-26 |
基那奥生物公司 |
用于将核酸递送到细胞的组合物和方法
|
EP4015634A1
(en)
|
2020-12-15 |
2022-06-22 |
Sylentis, S.A.U. |
Sirna and compositions for prophylactic and therapeutic treatment of virus diseases
|
MX2023010249A
(es)
|
2021-03-04 |
2023-09-15 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni de proteina similar a la angiopoyetina 3 (angptl3) y metodos para usarlas.
|
WO2022211740A1
(en)
|
2021-03-31 |
2022-10-06 |
Carmine Therapeutics Pte. Ltd. |
Extracellular vesicles loaded with at least two different nucleic acids
|
WO2022218941A2
(en)
|
2021-04-12 |
2022-10-20 |
Boehringer Ingelheim International Gmbh |
Compositions and methods for inhibiting ketohexokinase (khk)
|
CN117120613A
(zh)
|
2021-04-14 |
2023-11-24 |
迪克纳制药公司 |
用于调节pnpla3表达的组合物和方法
|
BR112023021614A2
(pt)
|
2021-04-19 |
2024-01-16 |
Dicerna Pharmaceuticals Inc |
Composições e métodos para inibir a expressão da subfamília 1 de receptores nucleares, grupo h, membro 3 (nr1h3)
|
JP7463621B2
(ja)
|
2021-05-28 |
2024-04-08 |
ノヴォ ノルディスク アー/エス |
ミトコンドリアアミドキシム還元成分1(marc1)発現を阻害するための組成物および方法
|
AU2022286925A1
(en)
|
2021-05-29 |
2023-12-21 |
1Globe Health Institute Llc |
Short duplex dna as a novel gene silencing technology and use thereof
|
AU2022285661A1
(en)
|
2021-05-29 |
2023-12-21 |
1Globe Health Institute Llc |
Asymmetric short duplex dna as a novel gene silencing technology and use thereof
|
CA3174095A1
(en)
|
2021-06-23 |
2022-12-29 |
Vignesh Narayan HARIHARAN |
Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
|
CN117795074A
(zh)
|
2021-08-03 |
2024-03-29 |
阿尔尼拉姆医药品有限公司 |
转甲状腺素蛋白(TTR)iRNA组合物和其使用方法
|
CA3229305A1
(en)
|
2021-08-16 |
2023-02-23 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
WO2023027759A1
(en)
|
2021-08-25 |
2023-03-02 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting αlpha-1 antitrypsin expression
|
CA3232054A1
(en)
|
2021-09-21 |
2023-03-30 |
Kannan Rangaramanujam |
Dendrimer conjugates of small molecule biologics for intracellular delivery
|
CA3234478A1
(en)
|
2021-11-11 |
2023-05-19 |
Souphalone LUANGSAY |
Pharmaceutical combinations for treatment of hbv
|
WO2023092089A1
(en)
|
2021-11-19 |
2023-05-25 |
Kist (Korea Institute Of Science And Technology) |
Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell
|
AR127843A1
(es)
|
2021-12-01 |
2024-03-06 |
Dicerna Pharmaceuticals Inc |
Composiciones y métodos para modular la expresión de apoc3
|
WO2023118546A2
(en)
|
2021-12-23 |
2023-06-29 |
Boehringer Ingelheim International Gmbh |
METHODS AND MOLECULES FOR RNA INTERFERENCE (RNAi)
|
WO2023159189A1
(en)
|
2022-02-18 |
2023-08-24 |
Yale University |
Branched poly(amine-co-ester) polymers for more efficient nucleic expression
|
GB202203627D0
(en)
|
2022-03-16 |
2022-04-27 |
Univ Manchester |
Agents for treating complement-related disorders
|
WO2023192872A1
(en)
|
2022-03-28 |
2023-10-05 |
Massachusetts Institute Of Technology |
Rna scaffolded wireframe origami and methods thereof
|
GB202204884D0
(en)
|
2022-04-04 |
2022-05-18 |
Fondo Ricerca Medica S R I |
Sirna targeting kcna1
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
TW202345873A
(zh)
|
2022-04-15 |
2023-12-01 |
美商戴瑟納製藥股份有限公司 |
調節scap活性之組合物及方法
|
WO2023220349A1
(en)
|
2022-05-12 |
2023-11-16 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting mapt expression
|
US20230416743A1
(en)
|
2022-05-13 |
2023-12-28 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting snca expression
|
TW202400193A
(zh)
|
2022-06-24 |
2024-01-01 |
丹麥商諾佛 儂迪克股份有限公司 |
抑制跨膜絲胺酸蛋白酶6(tmprss6)表現的組成物及方法
|
WO2024040041A1
(en)
|
2022-08-15 |
2024-02-22 |
Dicerna Pharmaceuticals, Inc. |
Regulation of activity of rnai molecules
|
WO2024081736A2
(en)
|
2022-10-11 |
2024-04-18 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
WO2024107993A1
(en)
|
2022-11-16 |
2024-05-23 |
Dicerna Pharmaceuticals, Inc. |
Stat3 targeting oligonucleotides and uses thereof
|
WO2024108217A1
(en)
|
2022-11-18 |
2024-05-23 |
Genkardia Inc. |
Methods and compositions for preventing, treating, or reversing cardiac diastolic dysfunction
|